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The digestive enzyme carboxyl ester lipase (CEL) is mainly expressed in the acinar cells of the 
exocrine pancreas. The protein contains a variable number of tandem repeats (VNTR) region, 
and the most common human form includes 16 VNTR repeats. We have previously identified 
disease-causing variants of CEL. One example is CEL-HYB1, which contains only 3 VNTR 
repeats and results in a truncated protein. Cellular studies of CEL-HYB1 have shown reduced 
secretion, intracellular accumulation and elevated ER stress compared to the normal CEL 
protein. Interestingly, CEL-HYB1 is a genetic risk factor for chronic pancreatitis that act 
together with other risk factors to trigger disease development. 
In this study, the main objective was to gain more insight into the disease mechanism of the 
CEL-HYB1 protein. More specifically, our aims were to study if environmental factors such as 
alcohol and cigarette smoking had any effect on the CEL-HYB1 protein by using both cellular 
and mouse models. Furthermore, we wanted to optimize a newly developed CEL-HYB1 
specific antibody for immunostaining. 
For most cellular studies on CEL, HEK-293 cells have been used, and with success. In this 
project, however, we wanted to use the mouse acinar cell line (266-6). But we found that both 
transfecting and detecting CEL protein expression in the 266-6 cells were challenging. 
Therefore, we optimized our research approach by transfecting the cells with V5-tagged CEL 
plasmids instead of untagged plasmids. By Western blotting we observed that CEL-HYB1 was 
less secreted compared to normal CEL, and also detected in the insoluble pellet fraction of 
transfected cells. By immunofluorescence, more intense intracellular signals were observed for 
CEL-HYB1 than for normal CEL. When the transfected 266-6 cells were treated with cigarette 
smoke extract (CSE) or ethanol (EtOH), there was a tendency of CEL-HYB1 increase in the 
pellet fraction when exposed to CSE. In contrast, we found no effect with EtOH.  
In addition to cellular models, we used a humanized CEL-HYB1 knock-in mouse strain to do a 
pilot experiment by subjecting the animals to ethanol feeding. After 3 weeks of exposure, we 
observed no features of chronic pancreatitis when analyzing the mouse pancreas histology. 
Furthermore, we detected no signs of increased ER-stress when analyzing pancreatic lysates by 
Western blotting.  
We tested the CEL-HYB antibody on cellular lysates from transfected 266-6 and HEK-293 
cells, and from mice pancreases by Western blotting. In addition, mouse and human pancreatic 
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tissue was analyzed by immunohistochemistry. After optimization, the antibody worked for all 
experiments, except for analysis of the 266-6 cells by immunoblotting.  
To summarize, we found reduced secretion and intracellular retention of CEL-HYB1 protein 
when expressed in 266-6 cells. This is similar to what has been reported in HEK-293 cells. We 
also observed CEL-HYB1 in the cell pellet fraction indicating CEL-HYB1 protein aggregation. 
When exposed to CSE, the level of CEL-HYB1 aggregation slightly increased. Finally, the 
CEL-HYB antibody was found to be specific for both Western blotting and 


















1. Introduction  
1.1 The pancreas-anatomy and function 
1.1.1The human pancreas  
The human pancreas is a glandular organ located in the upper left part of the abdominal cavity, 
lying horizontally behind the stomach (Figure 1.1A). The gland has an elongated structure and 
can be divided into a head, body and tail region (Kumar et al., 2017). The pancreas can weigh 
85-100 g (Caglar et al., 2014) and have a length of 15-20 cm in adults (Holck, 2019). It is the 
only organ in the body that contains an endocrine and an exocrine part. The endocrine pancreas 
consists of the islets of Langerhans, which produce hormones that are secreted into the 
bloodstream. The exocrine pancreas consists of acinar cells and the ductal system which 
produce, store and secrete digestive enzymes that are transported to the duodenum (Figure 1.1 




Figure 1.1 Anatomical overview, characteristics and histology of the pancreas. A) The human 
pancreas (yellow) is situated in the upper part of the abdominal cavity behind the stomach. Image from: 
https://www.mayoclinic.org/diseases-conditions/pancreatic-cancer/symptoms-causes/syc-20355421 B) 
The pancreas is divided into the endocrine and exocrine pancreas. The endocrine part consists of islets 
of Langerhans and secretes hormones while the exocrine part secretes digestive enzymes. Image from: 
https://socratic.org/questions/what-organ-functions-as-both-an-endocrine-and-exocrine-organ C) The 
image shows the histology of the pancreas where an islet of Langerhans (light pink) is surrounded by 
the acinar cells (dark pink/purple) of the exocrine pancreas.  
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1.1.2 The endocrine pancreas 
The endocrine pancreas consists of groups of specialized cells arranged in clusters called islets 
of Langerhans (Kumar et al., 2017). The islets make up around 1-2 % of the total organ and are 
scattered within the exocrine tissue. The main function of the endocrine pancreas is to secrete 
hormones into the bloodstream (Roder et al., 2016). Each islet has a central core of beta cells 
(60 %) surrounded by alfa (30 %), delta, gamma and epsilon (together 10 %) cells (Figure 1.2) 
(Da Silva Xavier, 2018). The beta cells are responsible for the expression and secretion of the 
peptide hormone insulin while the alfa cells produce and release the peptide hormone glucagon. 
Both insulin and glucagon work to maintain a stable blood-glucose level. When the blood-
glucose level rises, this will triggers the secretion of insulin to the bloodstream. The release of 
insulin stimulates an increased glucose uptake in muscle and other tissues and promotes the 
storage of glucose as glycogen in the liver. The result is a lowered blood-glucose level. 
Opposite, when the blood-glucose is low, glucagon is secreted. This results in the breakdown 
of glycogen into glucose to increase the concentration of blood-glucose (Lodish et al., 2016). 
The remaining cells of the islet of Langerhans, the delta, gamma and epsilon cells, produce the 











Figure 1.2 Schematic representation of the endocrine pancreas. Each islet of Langerhans is 
embedded within the exocrine tissue and consists of alfa, beta, gamma, delta and epsilon cells. The beta 
cells are the most abundant cell type and secrete and produce the hormone insulin, while the alfa cells 
secrete its antagonist glucagon. Figure adapted from: Bardeesy, N et al., 2002. Nat Rev Cancer  
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1.1.3 The exocrine pancreas 
The exocrine part of the pancreas makes up around 95 % of the total organ and consists of acini 
and a ductal system (Das et al., 2014). Acini are clusters of acinar cells which are responsible 
for the production and secretion of digestive enzymes. The acinar cells produce digestive 
enzymes in an inactive form (zymogens) to prevent autodigestion and the enzymes are stored 
in zymogen granules before they are released (Figure 1.3). The digestive enzymes are classified 
based on their target substrates and include amylases, lipases, proteases and nucleases which 
break down carbohydrates, fats, proteins and nucleic acids, respectively. The enzymes are 
secreted from the acinar cells into ducts via interlobular ducts (Pandol., 2011). The ductal cells 
produce and secrete bicarbonate and water, which together with the digestive enzymes 
constitute the pancreatic juice. This juice is transported to the duodenum where it mixes with 
bile from the liver and chyme from the stomach (Lopez et al., 2019), having a key role in the 
digestion of food. Each day, the pancreas produces 2-3 liters of juice in an adult (Ishiguro et 
al., 2012). The exocrine cells in the pancreas has the highest level of protein synthesis in the 
adult body. Thus, the acinar cells have an extensive endoplasmic reticulum (ER) network 
(Logsdon et al., 2013).  
Figure 1.3 Schematic representation of the exocrine pancreas. A) An acinus is a cluster of acinar 
cells, which are in contact with the ductal system. The digestive enzymes are secreted into the lumen of 
the acinus and transported to the duodenum via the ducts. Figure adapted from: Bardeesy, N et al., 2002. 
Nat Rev Cancer. B) The acinar cells contain an extensive network of ER and mitochondria located at 
the basal pole. The digestive enzymes are stored in the zymogen granules located at the apical pole. 
Figure adapted from: www.zoology.ubc.ca//~berger/B200sample/unit_9_secretion/workshope9-htm 
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1.2. Diseases of the pancreas  
The most common diseases of the pancreas are diabetes mellitus (commonly referred to as 
diabetes), neoplasms and inflammation (commonly referred to as pancreatitis).  
1.2.1 Diabetes mellitus 
Diabetes affects the endocrine part of the pancreas and is a group of metabolic diseases 
characterized by chronic hyperglycemia (Kumar et al., 2017). The disease is caused by defects 
in insulin secretion, insulin action or both. The majority of cases fall within two categories: 
type 1 diabetes (T1D) and type 2 diabetes (T2D) (American Diabetes Association, 2010). T1D 
makes up 5-10 % of all cases of diabetes and is an autoimmune disease resulting in beta-cell 
destruction and insufficient insulin production. Patients who suffer from T1D are often young 
when diagnosed (< 20 years) and they are dependent on insulin injections throughout life to 
control blood-glucose level (Kharroubi et al., 2015). Symptoms of T1D include increased thirst 
and appetite, fatigue and weight loss (Kahanovitz et al., 2017).  
T2D is a multifactorial disease that accounts for about 90 % of all cases of diabetes cases. Both 
genetics and an unhealthy lifestyle are well-known risk factors and the disease is characterized 
by an onset between the ages of 30-40 years and a relative insulin deficiency (American 
Diabetes Association, 2010). Often, patients with T2D do not need insulin replacements to 
survive. A healthy diet and physical activity can be enough, especially at disease onset. Still,  
many T2D patients require medications to lower blood-glucose level (Marin-Peñalver et al., 
2016). In addition to T1D and T2D, there are other forms of diabetes including gestational 
diabetes and monogenic diabetes. In gestational diabetes, hyperglycemia is detected during 
pregnancy whilst monogenic diabetes is caused by mutations in a single gene (American 
Diabetes Association, 2010).  
Diabetes is the fifth leading cause of death worldwide and as of 2019, 422 million individuals 
worldwide suffers from this disease (World Health Organization., 2020). Within 2035, 
researchers believe this number will rise to almost 600 million (Forouhi et al., 2014).  
 
1.2.2 Neoplasms of the pancreas  
Neoplasms are divided into benign and malignant, where malignant neoplasm are collectively 
referred to as cancers. Neoplasms of the pancreas can originate from both the exocrine and the 
endocrine pancreas (Kumar et al., 2017). The most common type of pancreatic cancer is 
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pancreatic adenocarcinoma, which arise from the exocrine part and accounts for about 85 % of 
all cases (Hidalgo et al., 2015). Risk factors associated with pancreatic cancer are divided into 
two categories: modifiable and non-modifiable. The modifiable risk factors include smoking, 
alcohol, obesity and toxic substances. Smoking and alcohol are also risk factors for other 
pancreatic diseases including pancreatitis. Some of the non-modifiable risk factors are gender, 
age, ethnicity, diabetes, family history and certain gene variants (Rawla et al., 2019). 
Worldwide, pancreatic cancer constitutes the seventh leading cause of cancer related deaths 
(Bray et al., 2018). In 2018, pancreatic cancer was the cause of more than 400,000 deaths 
worldwide accounting for 4.5 % of all cancer-related mortality. The prognosis for pancreatic 
cancer is poor as only 24 % of the patients survive one year after diagnosis (Rawla et al., 2019). 
Symptoms often include include jaundice, abdominal pain and weight loss (Kumar et al., 2017). 
Treatments for pancreatic cancer include surgical resection of the tumor, chemotherapy, 
radiation therapy and pain management (Vincent et al., 2011).  
1.2.3 Pancreatitis  
Pancreatitis is inflammation of the pancreas. The disease is usually divided into an acute and a 
chronic form (Kumar et al., 2017). The risk factors for acute pancreatitis include gallstones, 
alcohol, certain drugs, genetics and trauma, of which gallstones and alcohol abuse are the most 
common in adults (Forsmark et al., 2016). Acute pancreatitis is characterized by pancreatic 
swelling, fluid retention and pancreatic necrosis (Whitcomb, 2006). The pathogenesis of acute 
pancreatitis includes the autodigestion of the pancreas due to premature or inappropriately 
activation of digestive enzymes (Whitcomb, 2013).  
Worldwide, the yearly incidence of acute pancreatitis is 34 per 100 000 in the general 
population (Petrov et al., 2019). An increase in acute pancreatitis incidences have been reported 
(Yadav et al., 2013). This may be due to more obesity as this condition can promote gallstone 
formation. The mortality of acute pancreatitis is about 2 % but this can increase to 30 % if 
patients are older and suffers from other diseases (Forsmark et al., 2016., Yadav et al., 2013). 
The symptoms of acute pancreatitis include abdominal pain, nausea and vomiting (Chatila et 
al., 2019). Patients with acute pancreatitis are given appropriate nutrition, pain management 
and intravenous hydration (Forsmark et al., 2016; Chatila et al., 2019). If a patient is suffering 
from several attacks from acute pancreatitis, this is called recurrent acute pancreatitis. Recurrent 
acute pancreatitis is again risk factor for developing chronic pancreatitis (Yadav et al., 2009) 
which will be described in detailed in the next section. 
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1.3 Chronic pancreatitis  
Chronic pancreatitis is irreversible, long-standing inflammation of the pancreas that leads to 
permanent destruction of the pancreas parenchyma (Kleeff et al., 2017). The disorder is 
characterized by fibrosis, duct distortions, calcifications as well as pancreatic endocrine and 
exocrine dysfunction (Gardner et al., 2020). Symptoms of chronic pancreatitis are abdominal 
pain, weight loss, jaundice and maldigestion but the disease can also be clinically silent (Kumar 
et al., 2017). Patients who suffer from this disease also have an increased risk for the 
development of both diabetes and pancreatic cancer (Yadav et al., 2013). Treatment of chronic 
pancreatitis involves pain management, pancreatic enzyme replacements and proper diet. If the 
patient is smoking and/or suffering from alcohol abuse, cessation is necessary (Pham and 
Forsmark, 2018). However, currently, there is no cure for chronic pancreatitis (Kleeff et al., 
2017). 
The most common risk factors for chronic pancreatitis are recurrent attacks of acute 
pancreatitis, alcohol abuse, cigarette smoking and genetic predisposition (Kleeff et al., 2017). 
In western countries, alcohol abuse accounts for 40-70 % of all cases while cigarette smoking 
increases the risk for disease development in a dose-dependent manner (Lew et al., 2017). A 
study conducted by Yadav et al, found that five units of alcohol a day or more increased the 
disease risk (Yadav et al., 2009). In contrast, less than two drinks per day may have a protective 
effect against chronic pancreatitis as it has shown to inhibit a pro-inflammatory transcription 
factor (Lew et al., 2017).  
Genetic risk factors for chronic pancreatitis include variants of the PRSS1 (cationic 
trypsinogen), CFTR (cystic fibrosis transmembrane conductance regulator), SPINK1 (serine 
protease), CPA1 (carboxypeptidase A), CTRC (chymotrypsinogen C), and CEL (carboxyl ester 
lipase) genes (Mayerle et al., 2019). These risk factors can be further divided into various 
pathogenic pathways driving disease development and will be described in more detail in 
section 1.3.1. Among the genes listed above, three mutations in PRSS1 are known to cause 
autosomal dominant hereditary pancreatitis (Saluja et al., 2019). The others are genetic risk 
variants that together with other risk factors (e.g. cigarette smoking or alcohol abuse) cause 
disease. Thus, most often, it is not a single factor but the combination of several risk factors 
that leads to chronic pancreatitis (Kleeff et al., 2017). 
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1.3.1 Disease mechanism of genetic risk in chronic pancreatitis  
For more than a century, premature activation of pancreatic digestive enzymes was proposed 
to be the causative for pancreatitis (Saluja et al., 2019). In particular, inappropriate trypsin 
activity was the cornerstone for our understanding of pancreatitis as a disease characterized by 
autodigestion of the pancreatic tissue. Recently, new research has implemented new theories 
on the disease mechanism of chronic pancreatitis. These include risk factors that drive disease 
development through pathways alternative to uncontrolled digestive enzyme activation. 
Currently, three pathways are characterized namely the trypsin-dependent pathway, the 
misfolding-dependent pathway and the ductal pathway (Mayerle et al., 2019).  
The trypsin-dependent pathway 
This pathway involves pathogenic gene variants of PRSS1, SPINK1 and CTRC that result in 
increased activation of trypsinogen, the precursor of trypsin, in the pancreas (Sahin-Toth, 2017, 
Hegyi and Sahin-Toth, 2017). PRSS1 gene variants are often gain-of-function mutations that 
stimulate activation of trypsinogen either directly and indirectly (Hegyi and Sahin-Toth, 2017). 
Interestingly, three gene variants of PRSS1 have shown to cause hereditary pancreatitis 
(Mayerle et al., 2019). Protective mechanisms that prevent trypsinogen activation include 
trypsin inhibition by SPINK1 and degradation of trypsinogen by CTRC. Consequently, loss-of 
function variants of both SPINK1 and CTRC have shown to be associated with inappropriate 
trypsinogen activation and chronic pancreatitis development (Mayerle et al., 2019) . 
The misfolding-dependent pathway 
This pathway is related to gene variants that result in protein misfolding and endoplasmic 
reticulum (ER) stress (Mayerle et al., 2019). Elevated ER stress occurs when there is an 
imbalance between the folding of proteins and the functional demand that is placed on the ER. 
The stress may stem from alcohol, smoking, trauma or genetics, but either way it leads to an 
increase of BIP (GRP78) that binds to misfolded proteins within the ER lumen (Waldron et al., 
2018). BIP sends downstream signal to three pathways: PERK (PKR like ER kinase), IRE1 
(inositol-requiring protein-1) and ATF6 (activating transcription factor 6) which activate and 
promote the degradation of misfolded proteins, production of molecular chaperons and cell 
death (Cnop et al., 2017). These pathways all aid to restore homeostasis and are called the 
unfolded protein responses (UPR) (Alberts et al., 2015). Variants of PRSS1, CPA1 and CEL 
have all been implicated in the misfolding-dependent pathway of chronic pancreatitis risk. In 
addition to increased ER-stress, expression of these genes leads to decreased protein secretion 
and intracellular protein retention in cellular systems (Mayerle et al., 2019).  
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The ductal pathway 
The last pathway, namely the ductal pathway involves the CFTR, claudin 2 (CLDN2 ) and 
calcium-sensing receptor (CASR) gene variants. All these genes are expressed in pancreatic 
ductal cells (Mayerle et al., 2019). The CFTR gene encodes a chloride-bicarbonate channel and 
pathogenic variants in this gene disrupts the channel activity. The CLDN2 encodes a tight 
junction protein in pancreatic ducts (Mayerle et al., 2019). Both, CFTR and CLDN2 are 
important for secretion of chloride ions- and bicarbonate. The CASR gene, encoding a receptor, 
responds to high levels of calcium in the pancreatic juice by increasing the secretion of ductal 
fluid (LaRusch and Whitcomb, 2011). Experimental evidence suggests that all three genes are 
important for proper secretion of the pancreatic juice. However, further studies are needed to 
fully understand their association with chronic pancreatitis (Derikx et al., 2015).  
1.3.2 Model systems for studying chronic pancreatitis  
Experimental research into chronic pancreatitis involves both cellular and animal models. The 
cellular models that are most commonly used are human embryonic kidney cells 293 (HEK-
293) and rodent acinar cells (266-6: from mouse, AR42J: from rat). The HEK-293 cells have 
been a valuable tool since they are of human origin, easy to culture, maintain and transfect 
(Thomas et al., 2005). The downside of using HEK-293 is that they are not acinar cells. 
Furthermore, they are constitutively secretory cells and do not contain any zymogen granules 
or digestive enzymes. Therefore, the mouse tumor acinar (266-6) and the rat tumor acinar 
(AR42J) cell lines are in many respects more suitable model systems. These cell lines secrete 
digestive enzymes, can be transfected and provide a more suitable environment to study chronic 
pancreatitis However, as 266-6 and AR42J are cancer cell lines, they may exhibit different 
characteristics than normal acinar cells (Derikx et al., 2015) 
Most of the animal models established to study chronic pancreatitis are rodents. The models of 
chronic pancreatitis can be divided into obstructive, environmental, chemical and genetic 
models (Lerch and Gorelick, 2013). Both partial, selective or complete pancreatic duct 
obstruction have been used to develop chronic pancreatitis in animals. The progression of 
disease is dependent on the species used and sometimes needs to be combined with stimulation 
of pancreatic secretion (Lerch and Gorelick, 2013). Chemical models for chronic pancreatitis 
involve the caerulein-induced method where rodents are injected with caerulein for several 
weeks (Lerch and Gorelick, 2013). Here, high frequency of caerulein injections causes 
pancreatic fibrosis (Aghdassi et al,. 2011). Intraperitoneal injections of ethanol to rodents can 
be used as an environmental model to study chronic pancreatitis. This method, however, does 
 13 
not cause features characteristic of chronic pancreatitis alone, even with long-term 
administration. The administration of ethanol has to be combined with caerulein injections to 
cause pancreatic fibrosis (Lerch and Gorelick, 2013). This model has yet to be fully 
characterized but has proven to be an interesting in terms of understanding alcohol-induced 
effects on chronic pancreatitis.  
Genetic models are important tools to study chronic pancreatitis (Lerch and Gorelick, 2013). 
Although some genetic manipulations can recapitulate the features shown in patients, the effects 
can be complex and vary greatly among species (Lerch and Gorelick, 2013). In a study by Geisz 
and Sahin-Toth, they analyzed knock-in mice with a variant of the cationic trypsinogen gene 
(Geisz and Sahin-Toth, 2018). They found many of the histological criteria for chronic 
pancreatitis in mouse including fibrosis, atrophy, metaplasia, dilated ducts and destruction of 
the acini. Eventually, they also observed destruction of the islets of Langerhans as shown in 
Figure 1.4 (Geisz and Sahin-Toth, 2018). 
Figure 1.4 Histology of a genetic mouse model of chronic pancreatitis. In contrast to the control 
mouse (left), fibrosis, dilated ducts and fatty replacement was seen in both the early (middle) and late 
(right) stages of chronic pancreatitis. Figure adapted from: Geisz and Sahin-Toth, 2018. Nat 
Communications.  
Another genetic model is the CPA1 knock-in mouse which develops chronic pancreatitis  
(Hegyi and Sahin-Toth., 2018). In a follow up study by Orekhova et al, they used CPA1 
homozygous mouse and exposed them to ethanol-feeding. Here, the CPA1 mutant mice fed 
with ethanol showed an accelerated disease progression with a 2-fold higher histological score 
when comparing acinar cell loss  (Orekhova et al., 2020).  
1.4 Carboxyl ester lipase  
Carboxyl ester lipase (CEL), a digestive enzyme also known as bile salt-stimulated lipase 
(BSSL) and bile salt-dependent lipase (BSDL) (Johansson et al., 2018), is mainly expressed in 
the acinar cells of the pancreas. CEL is one of three lipases secreted from this organ and it 
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makes up around 4 % of the total protein content of the pancreatic juice (Lombardo et al., 1978). 
The protein is synthesized and modified before stored in zymogen granules within the acinar 
cells. CEL is then secreted in an inactive form and transported to the duodenum (Whitcomb et 
al., 2007). Here, the enzyme is stimulated by bile salts and hydrolyses various substrates such 
as phospholipids, triacylglycerides, fat-soluble vitamins and cholesteryl esters (Lombardo and 
Guy, 1980). It has also been proposed that the CEL can degrade branched fatty acid esters of 
hydroxyl fatty acids, which are metabolites with anti-inflammatory and anti-diabetic effects 
(Kolar et al., 2016). In addition, CEL is expressed in lactating mammary glands and secreted 
with the mother’s milk. Here, CEL has shown to be important for the digestion of fat in 
newborns (Blackberg et al., 1987, Lindquist and Hernell, 2010). CEL expression has also been 
detected at lower levels in macrophages (Kodvawala et al., 2005), eosinophils (Holtsberg et al., 
1995) and endothelial cells (Li and Hui, 1998).  
 
1.4.1 The human CEL gene 
The human CEL gene is about 10 kb in size and located on the long arm of chromosome 
9q34.13. The gene consists of 11 exons (Figure 1.5) where the last exon contains a variable 
number of tandem repeat (VNTR) region (Taylor et al., 1991, Lidberg et al., 1992). The repeats 
are nearly identical 33 bp segments that encode 11 amino acids each. The most common number 
of VNTR repeats is 16, although it ranges between 3 to 23 repeats (Torsvik et al., 2010, Fjeld 
et al., 2016).  
 
Situated 11 kb downstream of the CEL gene is the CEL pseudogene (CELP) (Lidberg et al., 
1992). Compared to CEL, the CELP gene is missing exon 2-7 of CEL and contains a stop codon 
in exon 8 (Figure 1.5). Otherwise, the two genes share 97 % sequence similarities. The CELP 







Figure 1.5 The gene structure of CEL and its neighboring pseudogene CELP. The CEL gene (blue) 
is about 10 kb in size and is situated next to its pseudogene CELP (green). The genes are located on 
chromosome 9. Exons 2-7 are only present in the CEL gene as indicated in the figure. VNTR; variable 
number of tandem repeat region. Drawn after:  Fjeld et al., 2015. Nat Genet 
 
 
1.4.2 The CEL protein and secretion 
The CEL protein has two structural domains; an N-terminal globular domain that contains the 
catalytic site, bile salt binding sites and a signaling peptide, and a C-terminal region with the 
VNTR domain  (Figure 1.6) (Reue et al., 1991, Terzyan et al., 2000, Holmes and Cox, 2011). 
The bile salt binding sites are located within the globular domain of the protein as is the catalytic 
triad of Ser194-His435-Asp320 (Holmes and Cox, 2011). The VNTR region contains 
enrichments of the amino acids proline (P), glutamate (E), serine (S) and threonine (T) (Figure 
1.6). This is known as a PEST sequence and is found to play a key role in protein degradation 
as it is observed in many short-lived proteins (Rogers et al., 1986).  
Figure 1.6 The protein structure of CEL. The protein comprises two structural domains: the N-
terminal globular domain containing both the signaling peptide (green) and the catalytic domain (blue), 
and the C-terminal VNTR region (grey). The figure also shows binding sites for bile salts, O-
glycosylation, N-glycosylation, phosphorylation, and the PEST sequence. Drawn after: Johansson et al., 
2018. Pancreatology 
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CEL is found to be a conserved protein that is a member of the α/β hydrolase family (More et 
al., 2011). Around 11 β-sheets makes up the core, which is surrounded by 15 α-helices (De Jaco 
et al., 2016). The CEL protein has a predicted molecular weight of 79 kDa and contains the 
distinctive C-terminal tail sequence KEAQMPAVIRF (Johansson et al., 2018). 
In the acinar cells, CEL follows the classical pathway of secretory proteins (Lombardo, 2001). 
The N-terminal hydrophobic signaling peptide of CEL directs the protein from the nucleus to 
the ER. Here, CEL is N-glycosylated at asparagine position 210, N210 (Figure. 1.6) (Aboukali 
et al., 1993). The protein is then relocated to the Golgi in association with a protein complex 
that contains the molecular chaperone GRP94 (glucose regulated protein, 94 kDa) (Bruneau et 
al., 1995). In the Golgi apparatus the protein is heavily O-glycosylated at both serine and 
threonine residues within the PEST sequence (Bruneau et al., 1997) (Figure. 1.6). The O-
glycosylation of CEL is important for the protein’s integrity as proteins lacking O-glycosylation 
are less secreted and more prone for degradation (Bruneau et al., 1997). As PEST sequences 
are observed in many short-lived proteins, there is a possibility that O-glycosylation is most 
likely masking the PEST sequences in CEL to prevent degradation (Rogers et al., 1986, Loomes 
et al., 1999).   
Once phosphorylated on threonine residue 340, CEL is released from the Golgi and stored as 
an inactive enzyme in the zymogen granules (Pasqualini et al., 2000). Upon stimulation, CEL 
is excreted from the luminal face of the acinar cells and transported to the duodenum. 
 
1.5 Pathogenic variants of CEL  
1.5.1 CEL-MODY 
CEL-MODY (MODY8) is an autosomal dominant inherited disease. In addition to diabetes, 
the patients are clinically characterized by a slowly progressing pancreatic exocrine dysfunction 
that includes both lipomatosis and the development of pancreatic cysts (Johansson et al., 2018). 
CEL-MODY is caused by single-base deletions in the first or fourth repeat within the CEL-
VNTR region. The mutations lead to a frameshift and a premature stop codon in VNTR repeat 
11 and 13, respectively (Ræder et al., 2006). The variants were identified in two independent 
families from Norway. However, CEL-MODY is a very rare disease. In addition to the 
Norwegian pedigrees, only two other families have been discovered: one from Sweden and one 
from the Czech Republic (unpublished). 
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Compared to the CEL-WT protein with a theoretical size of 79 kDa, the CEL-MODY proteins 
have a truncated C-terminal and a predicted size of about 73 kDa. Cellular studies from our 
research group indicate that CEL-MODY variants cause a protein-misfolding disease as this 
variant has a tendency to form aggregates both inside and outside the cell (Johansson et al., 
2011, Torsvik et al., 2014, Gravdal et al, unpublished). In addition, the CEL-MODY protein is 
less secreted and induces ER-stress when expressed in both HEK-293 and rat AR42J acinar 
cells (Xiao et al., 2016, Gravdal et al,unpublished). Recent studies have also shown that once 
secreted, the CEL-MODY protein can be taken up by neighboring cells and induce cell death 
(Torsvik et al., 2014, Dalva et al., 2020).  
 
1.5.2 CEL-HYB 
In 2015, our research group reported CEL-HYB as a novel genetic risk factor for chronic 
pancreatitis (Fjeld et al., 2015). In this study, cohorts of idiopathic chronic pancreatitis from 
both France and Germany were analyzed and CEL-HYB was overrepresented by five-fold in 
cases compared to healthy controls. The CEL-HYB allele was also found to be enriched in 
patients with alcohol-induced chronic pancreatitis (Fjeld et al., 2015).  
 
CEL-HYB is a deletion hybrid variant that has most likely originated from a process called non-
allelic homologous recombination (NAHR) between the CEL gene and the CEL pseudogene 
(CELP) (Fjeld et al., 2015). NAHR is a mechanism in which the cells aim to repair broken 
chromosomes resulting in gross genome rearrangements (Parks et al., 2015). NAHR usually 
happens between two genes that share a high sequence similarity, which is the case for CEL 
and CELP that share about 97 % sequence similarity in the common sequences. In addition to 
the deletion hybrid allele (CEL-HYB), the process has led to the formation of a reciprocal 
duplication allele (CEL-DUP) as illustrates in Figure 1.7 (Fjeld et al., 2015).  
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Figure 1.7. Proposed mechanism of how the CEL-HYB1 gene originated through non-allelic 
homologous recombination. The X symbolizes the crossover event in the exon 10–exon 11 regions of 
CEL and CELP. The resulting alleles are the duplication hybrid allele (CEL-DUP) and the deletion 
hybrid allele (CEL-HYB). Drawn after:  Fjeld et al., 2015. Nat Genet.  
 
The CEL-HYB gene encodes a chimeric protein where the globular domain is identical to the 
CEL-WT protein while the C-terminal VNTR region with only three repeats originates from 
CELP (Fjeld et al., 2015). When expressed in HEK-293 cells the CEL-HYB protein showed 
impaired secretion, induced autophagy and intracellular accumulation compared to CEL-WT 
(Fjeld et al., 2015). CEL-HYB was also found to have a 40 % reduced enzyme activity level 
compared to CEL-WT (Fjeld et al., 2015). Furthermore, in an unpublished study by our group, 
CEL-HYB showed induced ER-stress when expressed in HEK-293 cells (Tjora et al., 
unpublished). Based on these recent findings, we can now conclude that CEL-HYB belongs to 
the misfolding-dependent pathway of genetic risk in chronic pancreatitis (Tjora et al., 
unpublished). 
In contrast to the European cohorts, the CEL-HYB allele was not found to be associated with 
chronic pancreatitis in three independent cohorts from Japan, India and China, respectively 
(Zou et al., 2016). Actually, they found no CEL-HYB positive samples, but discovered an 
alternative CEL-HYB allele which they designated CEL-HYB2 (to distinguish it from the first 
identified CEL-HYB allele, which was renamed CEL-HYB1). The CEL-HYB2 allele was 
detected in all three Asian populations but exhibited no association with chronic pancreatitis. 
Compared to CEL-HYB1, CEL-HYB2 has a premature stop codon located in exon 10 that most 
likely results in nonsense-mediated mRNA decay (Nickless et al., 2017). Consequently, the 
expression and secretion of the CEL-HYB2 protein is predicted to be reduced as illustrated in 




Figure 1.8. C-terminal and cellular characteristics of CEL-HYB1 and CEL-HYB2 compared to 
CEL-WT. The most common CEL-WT protein usually consists of 16 repeats in the VNTR region. The 
CEL-HYB1 variant contains only 3 VNTR repeats that originates from the CEL pseudogene. CEL-
HYB1 is not secreted efficiently and leads to an increased risk for chronic pancreatitis. The CEL-HYB2 
variant has a premature stop-codon before the VNTR region. This results in nonsense-mediated mRNA 
decay and probably a reduced protein expression. The CEL-HYB2 variant is not associated with chronic 
pancreatitis. Figure is adapted from: Molven et al., 2016. Gastroenterology. 
 
Based on the results from the Asian populations, Zou et al suggested that the CEL-HYB1 allele 
is an ethnic-specific risk factor for chronic pancreatitis (Zou et al., 2016). To follow up on that, 
a recent study analyzed the CEL-HYB1 allele in a cohort consisting of pediatric chronic 
pancreatitis patients from Poland. Here, the frequency of CEL-HYB1 was found to be twice as 
high in cases compared with the control group although the difference did not reach statistical 
significance (Oracz et al., 2019).  
Compared to CEL-MODY, which results in a dominantly inherited, high-penetrant disease, 
CEL-HYB1 is “only” a risk factor for chronic pancreatitis. Thus, in CEL-HYB1 positive families 
the allele follows an autosomal dominant inheritance pattern with incomplete penetrance (Fjeld 
et al., 2015, Oracz et al., 2019). Furthermore, a relatively large number of healthy individuals 
are CEL-HYB1 positive. In the European populations studied so far, between 0.3 - 2.5% of the 
general population is estimated to carry the risk allele without being sick (Fjeld et al., 2015, 
(Dalva et al., 2016, Oracz et al., 2019). This indicates that it is not CEL-HYB alone that causes 
disease – it is CEL-HYB1 in combination with other chronic pancreatitis risk factors that 
triggers disease.  
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2. Aims 
The overall aim of this study was to gain more insight into the disease mechanism of the CEL-
HYB1 protein.  
The specific aims were:  
1. To investigate the effect of cigarette smoking extract and alcohol on CEL-HYB1- 
transfected mouse acinar cells  
 
2. To examine the effect of ethanol-feeding on a humanized CEL-HYB1 knock-in mouse 
strain.   
 
3. To test the specificity of a newly developed CEL-HYB antibody by using cell lysates, 















3. Materials  
Table 3.1 Plasmids 
Plasmid* Encoding Description 
pcDNA 3.1-CEL-WT/V5-His  CEL-WT Plasmid expressing the CEL wild type (WT) 
protein containing 16 VNTR repeats 
(Johansson et al., 2011) 
pcDNA 3.1-CEL-HYB1/V5-His  CEL-HYB1 Plasmid expressing the CEL-HYB1 protein 
(Fjeld et al., 2015) 
pcDNA 3.1CEL-TRUNC/V5-
His B 
CEL-TRUNC Plasmid expressing CEL-TRUNC, an 
artificial CEL protein lacking the VNTR 
domain (Johansson et al., 2011)  
pcDNA 3.1.CEL-HYB1N/V5-
His  
CEL-HYB1N Plasmid expressing CEL-HYB1 where an 
N-glycosylation site has been mutated in the 
C-terminal of the protein. New name: CEL-
HYB1N (unpublished) 
pcDNA 3.1/V5-His  EV Empty vector 
*All plasmids are based on the mammalian expression vector pcDNA3.1/V5-His B from 
Invitrogen 
Table 3.2 DNA methods 
Product Catalog number Supplier 
Ampicillin A9518-5G Sigma Aldrich 
BamHI restriction enzyme R0136S New England BioLabs 
CutSmart Buffer B7204S New England BioLabs 
OneShot TOP10 Chemically 
Competent E.coli cells 
C4040-03 Invitrogen 
Ethidium bromide E1510-10ml Sigma Aldrich 
Gel Loading Dye, Blue (6X) B7021S New England BioLabs 
imMedia Amp Agar 45-0034 Invitrogen 
Lysogeny broth (LB) medium SLBQ7430V Sigma Aldrich 
NuSieve  3-1 Agarose 7894 Lonza 
QIAfilterPlasmid Midi Kit (100) 12245 Qiagen 
TE buffer (pH 8.0) AM9849 Invitrogen 
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Table 3.3 Cell lines 
Cell line Description Catalog 
number 
Supplier 
266-6 Mouse pancreatic acinar tumor cell CRL-2151 ATCC 





Table 3.4 Cell culturing 
Product Catalog number Supplier 
Antibiotic Antimycotic 15240062 Thermo Fischer Scientific 
Dimethyl sulfoxide (DMSO) D8418-250ml  Sigma-Aldrich 
Dexamethasone D4902-25MG Sigma-Aldrich 
Dulbeccos Modified Eagles medium 41966-029-500ml Gbco by Life Technologies 
Dulbeccos Phosphate Buffered Saline RNBH2629 Sigma Aldrich 
Fetal Bovine Serum (FBS) F7524-500ml Sigma Aldrich 
0.05 % Trypsin EDTA (1x) 253000-054 -50ml Gibco by Life Technologies 
 
Table 3.5 Transient transfection and treatment of cells 
Product Catalog number Supplier 
Amaxa  SF Cell line 4D Nucleofector X Kit 
L 
V4XC-2024 Lonza 
Cigarette smoke extract (CSE) - Murty Pharmaceuticals 
Lipofectamine 2000 Reagent 11668019 Invitrogen 
Nunclon Delta Surface 6 well plates 140675 Thermo Scientific 
Opti-MEM Reduced Serum Medium 31985062 Thermo Fisher Scientific 





Table 3.6 Cell lysis, SDS-PAGE and Western blotting 
Product Catalog number Supplier 
Amersham Hybond 0.45 µm PVDF 
membrane 
10600029 GE Healthcare Life Science 
Blocking grade blocker nonfat-dry milk 170-6404 BioRad 
Blotto, nonfat-dry milk sc-2324 Santa Cruz Biotechnology Inc 
Magic Mark XP Western Protein Standard LC6502 Invitrogen 
Methanol 67-56-1 Merck Millipore 
NuPAGE LDS sample buffer (4x) NP0007 Thermo Fisher Scientific 
NuPAGE  MOPS SDS running buffer (20x) NP0001-01 Thermo Fisher Scientific 
NuPAGE  Novex 4-12 % Bis-Tris protein 
gels (1 mm, 10 wells) 
NP0321BOX Thermo Fisher Scientific  
NuPAGE Novex 10% Bis-Tris protein gels 
(1 mm, 10 wells) 
NP0301BOX Thermo Fisher Scientific 
NuPage Transfer Buffer (20X) NP0006-1 Thermo Fisher Scientific 
NuPAGE Sample reducing agent (10x) NP0009 Thermo Fisher Scientific 
Phosphate buffer saline (PBS) tablets 18912-014 Gibco 
Pierce BCA protein assay kit 23225 Thermo Scientific  
Pierce ECL Plus Western Blotting Substrate 32132 Thermo Scientific  
Precision Plus Protein  dual color standard 161-0374 Biorad 
Restore Western blot stripping buffer 21059 Thermo Scientific 
β-mecaptoethanol ) 60-24-2 Sigma Aldrich  








Table 3.7 Immunofluorescence 
Product Catalog number Supplier 
ProLong Gold Antifade Mountant with 
DAPI 
P36935 Molecular Probes 
Normal goat serum 1000C Invitrogen 
Nunclon Delta Surface 12 well plates 150628 Thermo Scientific 
Paraformaldehyde (PFA) 818715 Merck Millipore 
Poly-L-Lysine RNBD9368-10ml Gibco by Life Technologies 
Duran group microscope slides 23 550 13 Duran Group 
 
Table 3.8 Immunohistochemistry  
Product Catalog number Supplier 
DAKO pen S2002 Agilent DAKO 
Envision Flex Hematoxylin K8008 Agilent DAKO 
Normal goat serum (10 %) 50197Z Thermo Fisher Scientific 
Pertex Mounting Media  00811-EX Histolab 
Liquid DAB+ Substrate 
Chromogen System 
K3468 Agilent DAKO 
Target Retrieval Solution, pH 9.0, 
10x  
S2367 DAKO 
Target Retrieval Solution, Citrate 
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Goat anti-Rabbit IgG 
HRP 
65-6120 Thermo Fisher Western Blot 
Donkey anti-Mouse 
IgG HRP 
Sc-2306 Santa Cruz Biotechnology 
Inc 
Western Blot 
Mouse anti-Goat IgG 
HRP 
Sc-2354 Santa Cruz Biotechnology 
Inc 
Western Blot 
Donkey anti-Goat IgG 
HRP 




Mouse IgG (H+L) 
Cross-Adsorbed 
Secondary Antibody, 
Alexa Fluor 488 




RH531H Biocare Medical   Immunohistochemistry 
 
MACH3 Rabbit Probe RP531H Biocare Medical Immunohistochemistry 
 
Table 3.11 Buffers and solutions 
Buffer Method Composition 
TBE buffer (pH 8.3) Gel electrophoresis Tris-borate (45 mM) and EDTA (1 mM) 
NuPAGE MOPS SDS 
running buffer (1x) 
SDS-PAGE For 1 L: 50 ml NuPAGE ® MOPS 20x in 
950 ml dH20. 
NuPAGE Transfer Buffer 
(1x) 
Western Blot For 1L: 50ml NuPAGE ® Transfer buffer 
(20x) in 850 ml dH2O and 100 ml 
methanol. 
5 % milk in PBS-T  
(0.05 %) 
Western blot 2.5 g blocking grade blocker nonfat-dry 
milk in 50 ml PBS-T (0.05 %).  
PBS-T (0.05 %) Western blot For 1 L: 2 tablets of PBS dissolved in 1L 
dH2O with 0.05% Tween ® 20. 
RIPA lysis buffer Cell lysis  
(cells) 
10x RIPA lysis buffer (0.5 M Tris-HCl, 1.5 
M NaCL, 2.5 % deoxycholic acid, 10 % 
NP-40, 10 mM EDTA, pH 7.4) + 1 tablet 
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CompleteTM Mini EDTA-free protease 
inhibitors cocktail tablet  
RIPA lysis buffer Cell lysis 
(tissue) 
1x RIPA lysis buffer (25 mM Tris, 150 
mM NaCl, 1 % Triton X-100, 1 % sodium 
deoxycholate, 1 % SDS, pH 7.6) + 1 tablet 
Complete Mini EDTA-free protease 
inhibitors cocktail tablet 
Blocking buffer Immunofluorescence 5 % normal goat serum in washing buffer 
Washing buffer Immunofluorescence For 1 L: 2 tablets of PBS in 1 L dH2O. 
Permeabilization buffer Immunofluorescence 15 µl Triton X-100 and 15 µl Tween 20 
dissolved in 14.7 ml PBS.  
Fixative Immunofluorescence 6 % paraformaldehyde in 3 ml 1x 
Phosphate buffered saline 
Citrate-EDTA buffer  
(10 mM citric acid, 2 mM 
EDTA and 0.05 % Tween)   
Immunohistochemistry For 1 L: 1.92 g citric acid and 0.74 g EDTA 
in 1000 ml dH20. pH adjusted to 6.2 and 
addition of 0.5 ml Tween 
Sodium citrate buffer (10 
mM sodium citrate and 
0.05 % Tween) 
Immunohistochemistry For 1 L: 2.94 g tri-sodium citrate added to 
1000 ml dH20. pH adjusted to 6 and 
addition of 0.5 ml Tween.  
Glycine buffer (0.05 mM 
glycine) 
Immunohistochemistry For 1 L: 3.75 g glycine to 1000 ml dH20 
(pH 3.5). Mix 200 ml glycine buffer with 
5.7 ml 1M HCl.  
High salt antibody diluent  Immunohistochemistry 0.05 M Tris, 0.15 M NaCl, 1 % BSA, 0.015 
M Na-azide and 0.05 % Tween. Adjust pH 
to 7.4 
Low salt antibody diluent Immunohistochemistry 0.05 M Tris, 0.075 M NaCl, 1 % BSA, 
0.015 M Na-azide and 0.05 % Tween. 
Adjust pH to 7.4 
Endogen peroxidase 
blocking solution 
Immunohistochemistry 3 % (v/v) H2O2 in dH2O 
 
3.1 Animals 
Our research group has recently developed a humanized knock-in CEL-HYB1 mouse strain. 
The transgenic strain was made on the C57BL/6J background by GenoWay, Lyon, France, by 
using the Cre/LoxP system.  
A schematic representation of how the CEL-HYB1 strain was generated is shown in Figure 3.1. 
Only heterozygous CEL-HYB1 mice were used in this project. C57BL/6J (0/0) was used as 
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controls. Heterozygous CEL-HYB1 mice (0/ki) harbor the three VNTR repeats from the human 









Figure 3.1 Schematic representation of how the CEL-HYB1 mouse strain was generated. The 
mouse Cel VNTR was replaced by the human VNTR of CEL-HYB1 (Fjeld et al., 2015). 
 
Table 3.12 Mice work  
Product Catalog number Supplier 
Trident RIPA lysis buffer  GTX400005 100 ml GenTex 
Rodent Liquid Diet Lieber-DeCarli 82 Shake and 
Pour Control Diet 
F1259SP Bio-Serv 
Rodent Liquid Diet Lieber-DeCarli 82 Shake and 
Pour Ethanol Diet 
F1258SP Bio-Serv 









Table 3.13 Technical equipment  
Product Supplier 
NanoDrop ND-1000 Thermo Scientific 
Sceptre 2.0 handheld automated cell counter Millipore  
Countess II Automated Cell counter Thermo Fisher Scientific  
Leica Confocal SP8 Leica Microsystems 
Leica DM200 LED Leica Microsystems 
ChemiDoc MP Imaging System BioRad 
Gen 5 2.06 software Biotek 
Eppendorf centrifuge 5417C A/B Phil 
Heraeus multifuge 3S-R  Thermo Electron corporation  
Heraeus Fresco  21 Microcentrifuge Thermo Fisher Scientific  
Heraeus Megafuge 1.0 Thermo Fisher Scientific 
4D-Nucleofector  System Lonza 





Table 3.14 Analytical software  
Product Supplier 
LASV4.8 Leica Microsystems  
FIJI software ImageJ 
LAS X software Leica Microsystems 




4. Methods  
4.1 Plasmid preparation  
4.1.1 Transformation of OneShot TOP10 Chemically Competent E.Coli cells 
Transformation was conducted by a rapid chemical procedure as described by the manufacturer 
(Invitrogen). In brief, pcDNA3.1 plasmids encoding different CEL-variants (Table 3.1) were 
transformed into OneShot TOP10 Chemically Competent E. coli cells. One µl of plasmid (500-
1000 ng) was added to 25 µl of E. coli cells. The cells were spread onto pre-warmed (37 °C) 
agar plates containing the selection marker ampicillin (100 µg/ml) and incubated overnight 
(o/n) at 37 °C. 
4.1.2 Bacterial glycerol stocks and plasmid purification 
For each transformation, a single bacteria colony was picked and inoculated into a 25 ml culture 
of lysogenic broth (LB) medium containing ampicillin (100 µg/ml). The culture was incubated 
o/n at 37 °C with shaking at 250 rpm. A bacterial glycerol stock was made for each plasmid by 
diluting 500 µl of the bacteria culture with 500 µl of 50 % glycerol. The stocks were stored at 
-80 °C. For plasmid preparation, the bacterial culture was harvested by centrifugation at 4570 
x g for 40 min at 4 °C. Plasmid purification was performed according to the Qiagen Plasmid 
Midi Kit (100) protocol. The DNA pellet was added 150 µl of TE buffer (Table 3.2) and left 
o/n at room temperature (RT) to ensure that the pellet was properly dissolved. 
4.1.3 Determination of plasmid concentration and quality  
After purification, the DNA concentration and quality of the plasmids were determined by 
optical density (OD) and agarose gel electrophoresis.  
4.1.3.1 OD measurements  
The absorbance of 1.0 µl solution was measured by a NanoDrop ND-1000 spectrophotometer 
at 260 nm to determine the plasmid concentration. The 260/280 ratio was considered to estimate 
the DNA purity. A ratio of approximately 1.8 indicates a pure sample as RNA and DNA absorb 
at 260 nm. A ratio lower than 1.8 indicates protein or phenol contamination, while a ratio higher 
than 1.8 can indicate RNA contamination. The 260/230 ratio should range between 2.0-2.2 to 
indicate a pure DNA sample. A lower ratio could indicate impurities such as phenol or 
guanidine residues (Thermo Fisher Scientific, 2015). 
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4.1.3.2 Agarose gel electrophoresis  
To verify the quality of the DNA, the CEL plasmids were separated on a 1 % agarose gel. The 
gel contained 0.5 µg/ml ethidium bromide to visualize the DNA. Before loading the gel, a 
restriction digestion was set up for each plasmid using the enzyme BamHI (Table 3.2). The 
reaction was incubated at 37 °C for 1 h and then left at 80 °C for 20 min for inactivation. Both 
digested and undigested plasmids (500-1000 ng) were loaded onto the gel. 10 µl sample was 
mixed with 2 µl of Gel Loading dye Blue (6x) before loaded adjacent to a 10 kb molecular size 
marker. The gel was run in 1x TBE buffer (Table 3.11) at 90 V for 2 h. The ChemiDoc MP 
Imaging System was used for visualization.  
Table 4.1 Restriction digestion with BamHI 
Reagents Amount  
Plasmid DNA  1 µg 
10X CutSmart Buffer 5 µl 
BamHI  1 µl 
dH2O 43 µl 
Total volume 50 µl 
 
4.2 Cell culturing, transfection and treatment of cells 
4.2.1 Cell culturing  
Mouse pancreatic acinar cells, 266-6 (ATCC) and human embryonic kidney cells, HEK-293 
(CloneTech) were cultured in Dulbeccos Modified Eagle’s Medium (DMEM) with high 
glucose (4500 mg/ml) supplemented with 10 % fetal bovine serum and 100 U/ml Antibiotics 
Antimycotic. The cells were grown in a humidified atmosphere with 5 % CO2 at 37 °C in T75 
cm2 flasks if not stated otherwise.  
4.2.2 Passaging and seeding of cells  
Sub-culturing was done by removing the growth medium and washing the cells with 3 ml pre-
warmed PBS. Next, 1 ml 0.05 % Trypsin-EDTA was added for the cells to detach from the 
surface. Subsequently the cells were resuspended in growth media and an appropriate dilution 
of cells was transferred to a new T75 cm2 flask and added a total of 13 ml growth media. For 
experiments that required an exact number of cells, an aliquot of the resuspended cells (5 µl) 
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were diluted 1:100 in PBS before counted using a Scepter 2.0 cell counter or a Countess II 
Automated Cell Counter following the manufacturer’s protocol. 
4.2.3 Cell freezing and thawing 
Cells were grown to 80-90 % confluency in a T75 cm2 flask prior to freezing. The cells were in 
log phase growth when freezing to ensure recovery and optimum health when thawed (ATCC, 
2010). The cells were trypsinized as described above (section 4.2.2) and transferred to a 15 ml 
Falcon tube before centrifuged at 1000 x g for 4 min. The supernatant was removed, and the 
pellet resuspended in 5 ml freezing medium (10 % DMSO in complete growth medium). The 
cell suspension was aliquoted in cryo vials and placed in a container with isopropanol at -80 
°C. After 72 h, the vials were transferred to a nitrogen tank for long-term storage.   
Rapid thawing of cells is important to avoid DMSO to destroy the cell membrane (Baboo et al., 
2019). A cryo vial containing 1 ml of cells were thawed by rubbing between palms, resuspended 
in 5 ml pre-warmed complete growth medium and transferred to a T25 cm2 flask. The next day, 
medium was removed, and cells were added fresh growth medium to remove debris and DMSO 
residue.  
4.2.4 Transient transfection of 266-6 cells by nucleofection 
Prior to transfection, cells were grown to 70-80 % confluency in T75-flasks. Also, 72 h before 
transfection, 100 nM dexamethasone was added to the cells for proper differentiation of the 
266-6 cells into an acinar like-phenotype (Derikx et al., 2015).  
Transfection was performed using the Nucleofector 4D technology by Lonza according to the 
manufacturer’s protocol. Nucleofection, which is a sophistical form of electroporation, uses a 
combination of electrical parameters and solutions that need to be optimized specifically for 
each cell line. The transfection protocol presented here was carefully optimized for the 266-6 
cell line. An overview of the protocol is presented in Figure 4.2. In brief, cells were washed, 
trypsinated, resuspended in 5 ml DMEM and counted using the CellCountess II apparatus (step 
1). The cells (9 x 106) were centrifuged at 90 x g for 10 min at RT and the supernatant was 
removed. The cell pellet was resuspended in transfection mix consisting of 1 µg DNA, 82 µl 
SF solution and 18 µl S1 supplement. The transfection mix was transferred to cuvettes and 
pulsed by the DN-100 program (step 3). Next, 400 µl of low-calcium RPMI media was added 
to cuvettes and left to incubate at 37 °C for 10 min (step 4). 2/3 of the pulsed cell suspension 
was transferred to one well of the 6-well plate for Western blot analysis, whereas 1/3 of the cell 
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suspension was transferred to one well of the 12-well plates for immunostaining and confocal 











Fig 4.2 Transfection of 266-6 cells by nucleofection. Figure is taken from the Lonza 4D 
nucleofection protocol. 
 
4.2.5 Transient transfection of HEK-293 cells by Lipofectamine 
Prior to transfection, HEK-293 cells were seeded in a 6-well plate (4 x 106 cells per well) and 
grown to 60-70 % confluency. The transfection was executed as described by the Lipofectamine 
2000 manufacturer protocol. For each transfection, 4 µg DNA was diluted in 250 µl Opti-MEM 
media and incubated for 5 min at RT. Similarly, 10 µl Lipofectamine was diluted in 250 µl 
Opti-MEM media and subsequently the DNA mix was added to the Lipofectamine mix and 
incubated at RT for 20 min. Next, the lipid-DNA solution was added to the cells and incubated 
at 37 °C. After 4-6 h, the growth medium was replaced, and the cells further incubated for 48 h 
before SDS-PAGE and Western blot analysis. 
4.2.6 Treatment of 266-6 cells 
266-6 cells were treated with cigarette smoking extract (CSE) or ethanol. According to Murty 
Pharmaceuticals, the CSE is made by burning University of Kentucky 3R4F standard research 
cigarettes on a filter smoke machine. The cigarette smoke is condensed, stored and further 
extracted with DMSO by soaking and sonication. The CSE is packaged as 40 mg/ml (equivalent 
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to 3.6 cigarettes per ml). For treatment of our cells, 4 or 40 µg/ml CSE were used as these 
concentrations fall within the range of light smoking (equivalent to 5 cigarettes a day) and heavy 
smoking (equivalent to 25 cigarettes per day), respectively. For treatment with ethanol, 
concentrations of 10 mM or 50 mM were used. Ethanol at 10 mM corresponds to two drinks a 
day while 50 mM represents alcohol consumption typical of alcoholics. The cells were added 
CSE or ethanol 24 h post-transfection. The cells were grown for additional 24 h before further 
analysis.  
4.3 Preparation of cellular fractions  
4.3.1 Preparation of lysate, pellet and medium fractions 
Forty-eight hours post transfection analytical fractions were prepared from cells seeded in 6-
well plates. From each well, one ml medium was collected and centrifuged for 5 min at 14 000 
x g at 4 °C. The supernatant was transferred to a new tube and analyzed as the medium fraction. 
The cells were washed with 1 ml PBS and lysed in ice-cold 150 µl RIPA lysis buffer (Table 
3.11). The lysate was collected by a cell scrapper and sonicated on ice for 10 s x 5 with a 10 s 
interval. The tube was centrifuged for 20 min at 14 0000 x g at 4 °C. The supernatant was 
collected and analyzed as the soluble lysate fraction. The pellet was washed in 1 ml PBS 
centrifuged for 5 min at 14 000 x g and 4 °C. This step was performed twice. The PBS was 
removed, and the pellet was added 100 µl 2 x LDS loading buffer and 5 % β-mercaptoethanol, 
denatured at 95 °C for 5 min and analyzed as the insoluble lysate/pellet fraction. If not used 
immediately, all fractions were stored at -80 °C until further analysis.  
4.3.2 Determination of protein concentration  
The protein concentration of the lysate fractions was determined by using the Pierce BCA 
Protein Assay. Between 4-20 µg of total protein was used for SDS-PAGE and Western blot 
analysis. For the pellet and medium fraction, the volume loaded onto the SDS gel was identical 
to that of the corresponding lysate.  
 
4.4 SDS-PAGE and Western blotting 
4.4.1 SDS-PAGE 
For the lysate and media fractions, 20 µl samples were prepared as described in Table 4.3. 
Before loading the SDS-gel, the samples were denatured for 15 min at 56 °C. The insoluble 
pellet fractions were prepared as described above (section 4.3.1). All samples were loaded onto 
 35 
10 % NuPage Bis-Tris gels (1.0 mm, 10 wells) and separated by electrophoresis in a XCell 
SureLock Mini-Cell system. As molecular weight markers, 2 µl of Magic Mark XP and 4 µl of 
Precision Plus Marker were loaded onto the gels. The gels run in a 1x 3-(N-morpholino) 
propanesulfonic acid (MOPS) buffer at 90 V for 15 min and then at 180 V for 1 h.  
Table 4.3 Content of lysate and media fractions loaded onto the SDS-gel.  
Reagents Volume 
Sample/dH2O 12 µl 
β-mercaptoethanol (14.3 M)  1 µl 
Sample Buffer (x4) 2 µl 
Reducing Agent (x10) 5 µl 
Total volume 20 µl 
 
4.4.2 Western blotting 
After SDS-PAGE, the proteins were transferred to polyvinylidene fluoride (PVDF) membranes 
using the XCell Blot Module system as described by Invitrogen. Prior to transfer, the 
membranes were activated in 100 % methanol for 1 min, followed by 1 min rinse in dH2O. 
Blotting was performed at 30 V for 1 h in 1X NuPage transfer buffer containing 10 % methanol. 
The membranes were blocked in 5 % milk in PBS-T (0.05 %) at RT for 1 h before incubated 
with primary antibodies diluted in 1% milk in PBS-T (0.05 %) o/n at 4 °C. The primary 
antibodies used were anti-V5 (1:10 000), anti-CEL (1:5000, St. Louis), anti-CEL (1:5000, 
Sigma), anti-CEL-HYB (1:300) or anti-BIP (1:5000). Also, primary antibodies against the 
housekeeping proteins GAPDH (1:2000) and anti-actin (1:1000) were included as loading 
controls. The following day, the membranes were washed 3x 5 min in PBS-T (0.05 %) before 
incubated with HRP-conjugated secondary antibodies diluted 1:5000 in 1 % milk PBS-T (0.05 
%) for 1 h at RT. Next, the membranes were washed 1x 15 min and 3x 5 min in PBS-T (0.05 
%) before developed using the Pierce ECL Plus Western Blotting Substrate kit. For detection, 
the ChemiDocTM MP Imaging System was used. 
4.5 Immunostaining and confocal imaging 
266-6 cells were transfected by nucleofection (section 4.2.4) and seeded on coverslips coated 
with poly-L-lysine in 12 well plates. After 48 h, the cells were washed with pre-warm PBS (37 
°C) and fixed in 500 µl of 3% paraformaldehyde for 30 min. After fixation, the cells were 
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washed twice with PBS followed by storage in PBS at 4°C or staining as described below. All 
buffers used for immunostaining are described in Table 3.11, and all incubations were 
performed at RT if not stated otherwise. 
4.5.1 Immunostaining  
Cells were incubated for 3x 5 min in washing buffer before permeabilized for 20 min. Next, the 
cells were washed 3x 5 min and further incubated for 30 min in blocking buffer. For primary 
antibody incubation, the coverslips were added 40 µl of anti-V5 (1:1000 in blocking buffer) 
and incubated for 2 h. Cells were washed o/n at 4 °C and incubated with Alexa Fluor 488 anti-
mouse HRP-conjugated secondary antibody (1:200 in blocking buffer) for 1 h. After a second 
washing step o/n at 4 °C, the coverslips were rinsed in PBS before mounting onto objective 
slides in 10 µl of Prolong Gold Antifade solution with DAPI. The slides were set to harden o/n 
and then further stored at -20 °C.  
4.5.2 Confocal imaging 
Images were obtained using a Leica TCS SP8 STED 3x confocal microscope (Leica 
Microsystems) equipped with an HCX PL APO CS 100x objective (NA 1.4) using oil as 
immersion medium. The scan speed was set to 600 Hz and bidirectional X scanning was on. 
Diode 405 and Argon 488 lasers were used, and the zoom factor was set to 1.4 for all images. 
The microscope software LAS X was used for image acquisition. 
4.6 Immunohistochemistry 
Formalin Fixed Paraffin Embedded (FFPE) human or mouse pancreatic tissue sections (3-5 
µm) were placed onto Klinpath slides and dried o/n at 58 °C. Slides were stored at 4 °C until 
further analysis.  Human pancreatic tissue sections were obtained from a biobank at the 
Department of Clinical Medicine, University of Bergen. The biobank consists of biological 
material sampled from patients with pancreatic cancer and other diseases of the exocrine 
pancreas. The study has been approved from the Regional Ethical Committee of Western 
Norway (REK 2013/1772).  
Before starting, the slides were incubated once more at 58 °C for 5 min. Next, the slides were 
deparaffinized in xylene for 2x 5 min, rehydrated with decreasing ethanol concentrations (100 
%, 96 % and 80 %) for 2x 2 min each and washed in dH2O for 1 min while shaking. All washing 
steps were performed while shaking. The tissue sections were further incubated with retrieval 
buffer in a pressure cooker at 120 °C for 1 min and cooled down with running tap water. 
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Sections incubated with the anti-CEL antibody (1:200, Sigma) were retrieved in Tris-EDTA 
buffer (pH 9.0) whereas sections incubated with the CEL-HYB antibody (5 µg/ml) were 
retrieved in a sodium citrate buffer (pH 6.0, Table 3.11). Sections were washed 3x 5 min with 
PBS-T (0.05 %) and further blocked for 30 min at RT in 10 % goat serum (Table 3.8). Next, 
tissues were delineated with a DAKO pen and incubated with primary antibody in a humidified 
chamber o/n at 4 °C.  
The following day, the primary antibody was removed, and the sections were washed 3x 15 
min in PBS-T (0.05 %) and blocked with 3 % endogenous peroxidase (Table 3.11) for 10 min 
at RT. Detection of the primary antibody was performed with MACH3 anti-rabbit kit. First, 
sections were incubated with the probe followed by an HRP-conjugated polymer. Both 
incubations was performed at RT for 20 min and washing steps of 3x 5 min was done with 
PBS-T (0.05 %) after each step. Visualization was done with 3,3´-diaminobenzidine (DAB) as 
substrate. The sections were also stained for 10 min with hematoxylin to visualize the nuclei. 
Finally, the sections were dehydrated in increasing ethanol concentrations (80, 96 and 100 %) 
1 min each, followed by xylene for 2x 2 min. The sections were mounted in permanent 
mounting media and visualized using a Leica DM2000LED microscope with a LASV4.8 
software.  
4.7 Mice work 
4.7.1 Animals 
The mice were housed and bred at the Laboratory Animal Facility, Department of Clinical 
Medicine, University of Bergen. The mice were kept under standard conditions with a 
temperature of 21 °C, a humidity of 55 %, a light/dark cycle of 12 h and they were fed normal 
chow diet. During the experimental period, however, the animals were fed with liquid diets as 
described in more detailed in section 4.7.3. Only CEL-HYB1 heterozygous and control male 
mice were used in this study. 
4.7.2 Study approval 
Both animal breeding and the animal experiment were approved by the Norwegian Animal 
Welfare Agency (Mattilsynet) in December 2017 (FOTS IDs 13902 and 13510, respectively).  
4.7.3 Rodent liquid diets 
Two rodent liquid diets were used in this study, namely the Lieber-DeCarli Shake and Pour ´82 
Control diet and the Lieber-DeCarli Shake and Pour ´82 Ethanol diet. Both the control and 
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ethanol diet were prepared every second day, and the ingredients and amount needed to prepare 
the diets are listed in Table 4.6. In short, dry mix was added to autoclaved tap water and mixed 
with and without 95 % ethanol by vigorous shaking. The two diets here were again mixed as 
further described in the next section. If not used immediately, the diets were stored at 4 °C o/n. 
Table 4.6 Ingredients and amount needed to prepare the Lieber-DeCarli (LDC) Control 
and Ethanol diet 
Ingredients For 200 ml diet 
LDC-Control diet: 
RT tap water (autoclaved) 






RT tap water (autoclaved) 







4.7.4 Ethanol feeding of mice 
At the start of the experiments, the mice were 29 weeks old. The mice were housed in individual 
cages, and the liquid diets were their only source of food and water. Furthermore, the diets were 
given in glass feeding tubes as shown in Figure 4.7.  
 
 
Figure 4.7: Mice fed the 
liquid diet. All diets were 
prepared as described in 
section 4.7.3 and were given 
in a glass feeding tube. An 
adequate amount of diets were 
given daily.  
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The mice were pair-fed meaning that one mouse was given the control diet, the other the ethanol 
diet. For ethanol feeding of mice, it is obligatory to introduce the alcohol gradually and to start 
with an adaption week (Guo et al., 2018). During the first two days, the ethanol group was fed 
with the control diet to get used to the liquid diet and the feeding tubes. The following days of 
the adaption week, the ethanol group was given an increasing amount of ethanol as shown in 
Figure 4.8. For the last two weeks, the mice were fed with a 5 % ethanol diet. The ethanol diet 
was prepared by mixing LCD-Control diet and LDC-Ethanol diet (Table 4.6) as shown in Table 
4.7. The control mice were maintained on the control diet from the first to the last day of the 
experiment. 
Figure 4.8 An experimental outline for ethanol and control-feeding of mice. The ethanol fed group 
was given an increasing percentage of ethanol in their diet for the first week before maintained at 5 % 
ethanol diet for the last two weeks. The control group was fed on an isocaloric adjusted control diet (see 
Table 4.7) 
 
Another important principle for this experiment, is that the paired mice are fed the same 
amounts of calories (Guo et al., 2018). To ensure that, the food intake was measured daily (in 
ml) and corrected. Consequently, pair-fed mice were given the same amount of diet based on 
the lowest intake from the day before.  
The liquid diet was changed every day between 4 and 5 pm. At the end of week 3, all mice were 
euthanized by CO2. The pancreas and liver were isolated and flash-frozen on liquid nitrogen or 
fixed in 4 % paraformaldehyde for Western blot (section 4.4.2) and histology analysis (section 
4.5.7), respectively. 
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Table 4.7 Isocaloric adjustment during the adaptation week with diet mixture principle 
Days Portion of  
LDC-Control diet (%)  
Portion of  
LDC-Ethanol diet (%) 
1-2 100 0 
3-4 75 25 
5-6 50 50 
7 25 75 
To the end of feeding 0 100 
 
4.7.5 Histology 
Pancreas tissues were fixed in 4 % formalin before paraffin-embedded sectioning (3-5 µm) was 
performed. The sectioning, embedding and hematoxylin-eosin staining was performed by the 
histology laboratory at the Department of Pathology, Haukeland University Hospital.  
4.7.6 Lysis of mouse pancreatic tissue   
After the mice were sacrificed, ¼ of the pancreas was cut and put in 500 µl of ice-cold 1 X 
RIPA buffer and placed on ice (Table 3.12). The tissue was homogenized by a pestle (ten times) 
before placed on a rotating wheel for 20 min at 4 0C. Next, the tissue was centrifuged at 14 000 
x g for 15 min at 4 0C. The supernatant was collected and analyzed as the lysate fraction. The 
pellet was washed twice in 1 ml PBS and centrifuged for 5 min at 14 000 x g at 4 °C. Next, the 
pellet was added with 100 µl of 2x loading buffer with 2x reducing agent. The fractions were 
stored at -80 0C until analyzed by SDS-PAGE and Western blotting as described in section 
4.4.2. Before loaded onto the SDS-gel, the pellet was incubated at 95 0C for 15 min. For the 
lysate, the samples loaded were prepared as described in section 4.4.1 except that no β-




5. Results  
5.1 Isolation of plasmids and determination of DNA quality  
Plasmids encoding CEL-WT, CEL-HYB1, CEL-TRUNC or EV (empty vector) were 
transformed into E.coli bacteria and further purified by using a Qiagen Plasmid Midi Kit 
(sections 4.1.1 and 4.1.2, respectively). Next, OD measurements were performed to estimate 
DNA concentration and quality. In addition, the plasmids were analyzed by agarose gel 
electrophoresis to confirm purification success. The plasmids were linearized with the 
restriction enzyme BamHI, and both cut and uncut plasmids were analyzed on the gel (Figure. 
5.1). For the digested plasmids we observed the expected band sizes around  7.3 kb for CEL-
WT, 7.1 kb  for CEL-HYB1, 6.8 kb for CEL-TRUNC and 5.5 kb bp for EV, respectively. For 
all undigested plasmids, the supercoiled form of the plasmid was detected as a strong band a 
bit lower than the respective linearized sample. In addition, a very weak upper band was seen 
that most likely represent open circular forms of the plasmids. Taken together, these results 
confirmed that the plasmids were intact and of good quality. 
Figure 5.1 Verification of plasmids by agarose gel electrophoresis. Plasmids (500-1000 ng) were 
loaded and separated on a 1 % agarose gel before stained with ethidium bromide. The plasmids were 
linearized with BamHI and digested/undigested plasmids are indicated with (+)/(-), respectively. Arrows 
point to weak bands that may correspond to open circular plasmids of undigested samples. 
 
5.2 Protein structure of CEL variants 
The plasmids used in this study are encoding different CEL variants, and a schematic overview 
of these proteins is presented in Figure 5.2. For CEL-WT, we used the variant with 16 VNTR 
repeats, which is the most common CEL protein in the general population. In addition to CEL-
WT and CEL-HYB1, we included an artificial CEL variant; CEL-TRUNC. This variant only 
 42 
harbors the first four amino acids of the first VNTR. This variant was included as a control to 
study the biological effect of an absent VNTR region  
 
Figure 5.2. Schematic overview of CEL protein variants employed in this study. CEL protein 
variants are presented with their functional domains and sites, theoretical size (kDa) and VNTR length 
indicated. All variants share identical signaling peptide (green) and globular domain (blue). The CEL-
WT protein has 16 VNTR repeats (grey), CEL-HYB1 has three VNTR repeats (red) whereas CEL-
TRUNC lacks the VNTR region expect for four amino acids of the first repeat (dark blue). Drawn after: 
Fjeld et al., 2015. Nat Genet and Johansson et al., 2018. Pancreatology.  
 
5.3 Expression of CEL protein variants in cell model systems 
All functional studies on the CEL-HYB1 protein has been performed using non-pancreatic 
human HEK-293 cells by our group (Fjeld et al., 2015, Tjora et al., unpublished). Now, we 
wanted to use the 266-6, which is a mouse acinar cell model, to study the CEL-HYB1 protein 
in a more suitable environment. Previous attempts to use the 266-6 cells have proven difficult 
using transfection by Lipofectamine as the transfection efficiency was only ~20 %. We 
therefore set out to try nucleofection as a new transfection approach.   
5.3.1 Optimization of cell transfection using nucleofection 
For optimization, 266-6 cells were transiently transfected with a vector encoding green 
fluorescent protein (GFP). GFP is often used as a reporter to determine transfection efficiency 
(Zizzi et al., 2010) and the percentage of cells expressing GFP in a population can be determined 
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by microscopy. Different amounts of cells were seeded to determine optimal transfection 
efficiency for immunofluorescence (IF) and Western blot (WB) experiments (section 4.5.1 and 
4.4.2, respectively). Forty-eight h post transfection, images were taken to determine the 
transfection efficiency.  
For IF, cells were seeded in 12-well plates at different densities as indicated in Figure 5.3A. 
The best transfection efficiency was observed with 6 million cells/well. However, we decided 
to use 3 million cells/well to avoid confluent cells for proper staining and visualization. For 
WB, cells were seeded in 6-well plates (Figure 5.3B). Here, best transfection efficiency was 
seen for 6 or 9 million cells/well. Since 9 million cells/well showed more cell death than 6 













Figure 5.3 Optimization of nucleofection of 266-6 cells. A titration of different number of cells/well 
were performed to determine optimal transfection efficiency for 266-6 cells. The cells were transfected 
with a vector encoding GFP. Cells expressing GFP are seen in green. A) For immunofluorescence, 
500,000, 1.5 million, 3 million or 6 million transfected cells were seeded per/well in 12-well plates. B) 
For Western blot, 4, 6, 8 or 9 million transfected cells were seeded per/well in 6-well plates. This 
experiment was conducted once. 
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5.3.2 Expression of CEL in 266-6 and HEK-293 cells 
Once the nucleofection method was optimized for the 266-6 cells, they were transiently 
transfected for investigation of CEL protein expression and secretion with plasmids encoding 
CEL-WT, CEL-HYB1 or CEL-TRUNC. Empty vector (EV) was included as a negative control. 
48 h post transfection, cell fractionation was performed for isolation and analysis of lysate, 
pellet and media fraction by Western blotting (section 4.3.1 and 4.4.2). Protein expression was 
detected by using either the anti-CEL (Sigma, cat.nr.  SAB2103782) antibody or anti-CEL (St. 
Louis) antibody (Figure 5.4). Anti-GAPDH was used as a loading control for the lysates.  
When using the CEL antibody from Sigma, only the CEL-WT protein was detected (Figure 5.3 
A, left panel). This was expected since the antibody recognizes the VNTR region of the CEL-
WT protein. The WT protein was observed in both the lysate and media fraction. In the media 
fraction, two bands were detected between 120 and 100 kDa. In the lysate fraction, one strong 
CEL-WT band was seen close to 100 kDa. These CEL-WT bands represent different 
glycosylated forms of the protein (Johansson et al., 2011, Torsvik et al., 2014). In addition, one 
unspecific band between 60 and 80 kDa was detected in all wells.  
The Western blot results when using the anti-CEL (St. Louis) antibody are shown in Figure 
5.3A (right panel). This antibody recognizes the globular domain of the CEL protein and was 
therefore expected to detect all CEL variants. To our surprise, however, only CEL-WT was 
detected here as well, in the medium and the pellet fractions.  
In previous experiments done by our research group, the anti-CEL (St. Louis) antibody worked 
well to detected various CEL proteins including CEL-HYB1 and CEL-TRUNC by Western 
blotting (unpublished data). The only difference was that the expression system had been HEK-
293 and not  266-6 cells which were used in the present study. To test if the lack of CEL protein 
detection in our study was due to the choice of cell model or a possible error in the CEL-
expressing plasmids, HEK-293 cells were transiently transfected with Lipofectamine using the 
same constructs as described above (section 4.2.5). Western blot analysis of the three cellular 
fractions is shown in Figure 5.4B. Now, all CEL variants could be detected. In the media 
fraction, only the CEL-WT protein was detected (between 100 and 120 kDa). In the pellet 
fraction, however, strong bands were observed for both CEL-HYB1 (about 65 kDa) and CEL-
TRUNC (about 60 kDa). In the same fraction, also a weak band was seen for the CEL-WT 
protein (about 80 kDa). In the lysate, a strong CEL-WT band and more faint CEL-HYB1 and 
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CEL-TRUNC bands were seen at similar sizes as described above. Similar to the left panel of 
Figure 5.4A, there were unspecific bands detected in the lysate fractions for all variants.  
Figure 5.4. Expression of CEL in 266-6 cells and HEK-293 cells.  A) The 266-6 cells were transiently 
transfected by nucleofection with plasmids encoding CEL-WT, CEL-HYB1, CEL-TRUNC or EV. 
Media, pellet and lysate fractions were analyzed by SDS-PAGE and Western blotting using an antibody 
that recognizes the VNTR region of the CEL-WT protein (Sigma) or an antibody that that recognizes 
the globular domain of the CEL protein (St. Louis). GAPDH was used as a loading control. B) HEK-
293 cells were transiently transfected by Lipofectamine with the same plasmids as in A. Media, lysate 
and pellet fractions were isolated and analyzed by SDS-PAGE and Western blotting by using the anti-
CEL (St. Louis) antibody and GAPDH as a loading control. This experiment was conducted one time. 
 
Taken together, the three tested CEL variants were detected at the expected molecular size when 
expressed in HEK-293 cells but not 266-6 cells. This indicates that the constructs were fine, 
and that the differences observed was due to the choice of cell line. The CEL-HYB1 was only 
observed in the pellet fraction in HEK-293 cells. Further, CEL-HYB  has been reported to be 
more insoluble in previous studies (Tjora et al., unpublished).  
 
5.4 Expression of V5-tagged CEL variants in 266-6 cells 
Since we failed to detect CEL expression in transfected 266-6 cells, we decided to change 
approach by transfecting the cells with V5-tagged plasmids. Our research group have made 
such plasmids for several CEL variants including CEL-WT, CEL-HYB1 and CEL-TRUNC, 
and they have all been used with success (Johansson et al., 2011, Fjeld et al., 2015). A schematic 
overview of the CEL protein variants encoded by the V5-tagged plasmids is presented in 
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Appendix 1. The V5-tag is located in the  C-terminal of CEL and is attached to the protein by 
a linker region.  
Now, we also included a second CEL-HYB1 plasmid for some of our experiments, to 
investigate if there was any difference in expression or intracellular distribution between the 
two CEL-HYB1 variants. In the new CEL-HYB1 variant (denoted CEL-HYB1N, see Appendix 
1), two serine residues was mutated in the linker region between the protein and the V5-tag. 
These two residues were introduced into the original CEL-HYB1 construct by accident (Fjeld 
et al., 2015), and since they could introduce an extra N-glycosylation they were now changed 
to alanine and glycine, respectively. Thus, CEL-HYB1N was included in this study to 
investigate the effect of the potential N-glycosylation site introduced to the C-terminal of CEL-
HYB1 
5.4.1 Western blot analysis of different CEL protein variants in 266-6 cells 
The 266-6 cells were nucleofected and fractionated 48 h post transfection as previously 
described. The cell fractions were isolated and analyzed by Western blotting using an anti-V5 
antibody and GAPDH as loading control.  
Figure 5.5 displays the Western blot analysis of V5-tagged CEL variants. In the media and 
lysate fractions, CEL-WT and CEL-HYB1 proteins were detected. In addition, a faint CEL-
TRUNC band was observed in the media fraction. Furthermore, unspecific signals were seen 
in the media and could be IgG heavy chain bands at around 50 kDa. Only the CEL-HYB1 
protein was observed in the insoluble pellet fraction indicating that this variant is less soluble 
than the normal protein also when expressed in acinar cell. 
 
 
Figure 5.5 Expression of different CEL protein 
variants in 266-6 cells. The 266-6 cells were 
nucleofected with plasmids encoding CEL-WT, CEL-
HYB1, CEL-TRUNC or EV containing a V5-tag. 
Media, pellet and lysate fractions were analyzed by 
SDS-PAGE and Western blot using an anti-V5 
antibody. As a loading control GAPDH was used. The 
figure is representative for three individual 
experiments.  
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Based on these results, we decided to use the V5-tagged plasmids for transfection of 266-6 cell 
throughout this master project. 
 
5.4.2 Immunofluorescence and confocal analysis of 266-6 cells 
To further investigate how the CEL protein variants distributes in the 266-6 cells, 
immunofluorescence and confocal imaging was performed on transiently transfected cells. The 
cells were fixed and stained 48 h after transfection and CEL proteins were detected by using an 
anti-V5 primary antibody and the secondary antibody Alexa Fluor 488 (green). DAPI was used 
to visualize the nuclei. (section 4.5.1 and 4.5.2.) 
In this experiment, the cells were transfected with plasmids encoding CEL-WT, CEL-HYB1, 
CEL-TRUNC and EV. In addition, the CEL-HYB1N variant was included to investigate if there 
was a difference between the two CEL-HYB1 variants.  
Confocal images of the immunostainings are presented in Figure 5.6. Interestingly, we saw that 
many of the cells clustered together to form acini-like structures. For the CEL-WT expressing 
cells, the protein was weakly detected within the lumen of such an acinus. A similar expression 
pattern was observed for both CEL-HYB1 variants, however with much stronger signals. 
Furthermore, CEL-HYB1 showed a more intense signal than the CEL-HYB1N variant. The 
CEL-TRUNC variant displayed a different expression pattern than the other variants. Here, less 
signals were observed, and the protein formed small clusters close to the nuclei.  
Interestingly, more cell death was observed for the CEL-HYB1 variant than for the CEL-WT, 
CEL-TRUNC and the CEL-HYB1N variant. The transfection efficiency, in all three 






Figure 5.6 Intracellular distribution of CEL variants in 266-6 cells. Transiently transfected 266-6 
cells expressing different CEL variants were fixed and stained 48 h post transfection using an anti-V5 
antibody followed by a secondary antibody (Alexa Fluor 488, green) for detection. DAPI was used to 
visualize the cell nuclei (blue). Cells were analyzed by a Leica SP8 confocal microscope at 100x 
magnification. The scale bar is set to 10 µm. The figure is representative for three individual 
experiments. 
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5.5 The impact of ethanol and cigarette smoke extract on CEL-HYB1 protein expression  
To investigate the effect of CEL-HYB1 in combination with environmental factors, we exposed 
acinar 266-6 cells to ethanol (EtOH) and smoke extract (CSE). Dexamethasone treated 266-6 
cells were nucleofected with plasmids encoding CEL-WT, CEL-HYB1, CEL-TRUNC, CEL-
HYB1N and EV (section 4.1.1). Twenty-four h post transfection, the cells were treated with low 
or high doses of CSE (4 and 40 µg/ml) or ethanol (10 and 50 mM), respectively. The cells were 
incubated for additional 24 h, fractionated into lysate, pellet and media fractions and analyzed 
by Western blotting (section 4.2.4. and 4.4.). As controls, untreated cells and/or cells treated 
with DMSO (equal to 40 µg/ml CSE) were used.   
Figure 5.7 shows the Western blot analysis of cells treated with CSE. For the control panel, one 
strong CEL-WT band and two weaker bands for CEL-HYB1 and CEL-HYB1N, respectively, 
were observed in the media fraction. In the pellet, only the CEL-HYB1 variant was detected. 
The CEL-HYB1N was not observed which could be due to an air bubble. In the lysate fraction, 
all CEL variants were detected.  
For the DMSO treated cells, the CEL-WT variant showed a strong band in the media and a 
fainter signal in the lysate fraction. For the CEL-HYB1 variants, they were only observed in 
the pellet. As for CEL-TRUNC, it was not detected at all.  
The cells exposed to low dose of CSE (4 µg/ml) showed a similar expression pattern as the cells  
treated with DMSO, except that the CEL-HYB1N had a stronger band than CEL-HYB1 in the 
pellet. In contrast, cells exposed to 40 µg/ml CSE showed CEL-WT, CEL-HYB1 and CEL-
HYB1N in the media fraction. In the lysate fraction, all variants were detected, and in the pellet 








Figure 5.7 The effect of CSE on CEL protein variants. Dexamethasone treated 266-6 cells were 
transfected with V5-tagged constructs encoding CEL-WT, CEL-HYB1, CEL-HYB1N, CEL-TRUNC or 
EV. Twenty-four h post transfection, cells were exposed to 4 or 40 µg/ml CSE for 24 h. As controls, 
untreated and DMSO treated cells were used. The cells were fractionated into media, pellet and lysate 
fractions and analyzed by SDS-PAGE and Western blotting using an antibody that recognizes the V5-
tag. Anti-GAPDH antibody was used for loading control. The experiment was performed once. 
 
The effect of ethanol on CEL variants is shown in Figure 5.8. The control panel displayed 
different patterns compared to the control panel for CSE treated cells (Figure 5.7). Here, only 
the CEL-WT was observed in the media while CEL-HYB1N and a faint CEL-HYB1 band were 
seen in the pellet fraction. In the lysate fraction, none of the variants were detected.  
The same expression pattern was observed in the cells exposed to 10 mM EtOH. After treatment 
with 50 mM EtOH, however, none of the variants were observed in the media and lysate 
fractions. Weak bands of CEL-HYB1 and CEL-HYB1N were observed in the pellet fraction 













Figure 5.8 The effect of EtOH on CEL protein variants. The 266-6 cells were transfected with V5-
tagged constructs encoding CEL-WT, CEL-HYB1, CEL-HYB1N, CEL-TRUNC or EV. Twenty-four h 
post transfection, cells were treated with 10 or 50 mM EtOH. As a control, untreated cells were used. 
Twenty-four h post treatment, cells were fractionated into media, pellet and lysate fractions and analyzed 
by SDS-PAGE and Western blotting and detected by anti-V5 antibody. GAPDH was used as a loading 
control. One parallel of this experiment was conducted 
 
In summary, the CEL-HYB1 variants tended to have stronger bands in the pellet fractions for 
cells treated with 4 and 40 µg/ml CSE compared to DMSO. In addition, the CEL-HYB1N 
variant exhibited stronger bands than the CEL-HYB1 variants when exposed to CSE. This 
pattern was not detected for the EtOH treated cells. However, CEL-HYB1N showed a stronger 
band than CEL-HYB1 in all pellet fractions.  
 
5.6 The effect of ethanol on transgenic CEL-HYB knock-in mice 
To study the effect of EtOH on transgenic CEL-HYB1 (0/ki) mice, we used 29-week-old male 
animals. C57BL/6N (0/0) mice were included as controls. The mice were pair-fed with control 
or EtOH-containing liquid diet as described in section 4.7.3. In short, after a 7-day 
acclimatization period (see Figure 4.8) the mice were fed a Lieber-DeCarli ethanol-containing 
(5 % v/v) liquid diet for 2 weeks. The pair-fed control group received an ethanol-free liquid 
diet for 2 weeks. The mice were sacrificed after 3-week with liquid feeding. This experiment 
was set up as a pilot and we included 3 pairs of mice: two controls (0/0, pair 1 and 2) and one 
CEL-HYB1 (0/ki, pair 3).  
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5.6.1 Food consumption and body weight 
Average food consumption was around 20 ml when the experiment started. Then, the  food 
intake decreased to about 15 ml when the ethanol diet was introduced and remained at this level 
throughout the experiment. Daily weighing showed that the control fed group gained weight 
during the three weeks while the EtOH fed group lost weight. (see Appendix 2 for growth 
curves).  
5.6.2 Pancreas histology of EtOH-fed mice 
After sacrificing the mice, one part of the pancreas was isolated and fixed for histological 
analysis (section 4.7.5.). Hematoxylin-eosin staining of pancreas sections from control- and 
ethanol-fed mice are shown in Figure 5.9. The histology of the pancreas in all mice, independent 
of diet, appeared normal. There was no sign of fibrosis or other features indicating chronic 
pancreatitis. The 0/ki mice fed with the control diet showed some fat in the pancreas. However, 
this is most likely due to body weight as this mouse was heavier than the other animals (see 











Figure 5.9 Effect of EtOH-feeding on pancreas histology. Pancreas sections from controls (0/0, pair 
1 and 2) and CEL-HYB1 (0/ki, pair 3) mice were stained with hematoxylin-eosin. Upper panel: Control 
mice; Lower panel: EtOH treated mice. I; Islets of Langerhans, E; exocrine pancreas D; Duct, F; Fat, B; 
Blood vessel. All images are 20x magnification and this experiment was performed once. Control, 
control liquid diet; EtOH, ethanol-containing diet. The experiment was performed once.  
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5.6.3 CEL and BIP expression in the pancreas of ethanol-fed mice  
Even though we found no signs of histological changes in the pancreas of ethanol-fed mice, we 
wanted to investigate if ethanol could induce cellular stress in the organ. To do so, we isolated 
pancreatic lysates and insoluble pellet fractions from both control and ethanol-fed mice (section 
4.7.6), and these fractions were further analyzed by Western blotting (Figure 5.10). As a stress 
marker, we used an antibody towards the ER-chaperone BIP. BIP is a master regulator of the 
unfolded protein response and is responsible for proper folding and assembly of proteins. The 
predicted molecular weight of BIP is 78 kDa. In addition, we analyzed CEL expression in the 
mice using the anti-CEL (St. Louis) antibody.  
The lysate fractions were analyzed for CEL expression. Here, we observed endogenous Cel 
expression in all mice at expected size around 66 kDa. The mouse Cel protein has a shorter 
VNTR region (only 3 repeats) and is therefore smaller in size compared to the normal human 
CEL protein (16 VNTR repeats). For the CEL-HYB1 mice, we observed an additional band 
(marked with an arrow in Figure 5.11). This corresponds to the humanized CEL-HYB1 protein 










Figure 5.10. The effect of EtOH on CEL and BIP expression in the pancreas from EtOH-fed mice. 
Mouse pancreatic lysates and pellet fractions were analyzed by Western blotting. Both endogenous and 
exogenous CEL expression was detected using a CEL specific antibody (St. Louis) whereas an anti- BIP 
antibody was used to detect ER-stress. Anti-β-actin was used as a loading control. Arrow indicates CEL-
HYB1 (64 kDa). This experiment was performed once. 
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The pellet fractions were analyzed for the ER stress marker BIP. A band around 80 kDa was 
observed for all samples, with a varying intensity.  However, the introduction of EtOH exposure 
did not have an obvious impact on BIP or CEL protein expression compared to the untreated 
mice.  
 
5.7 Testing of a new CEL-HYB specific antibody 
5.7.1 The CEL-HYB antibody  
The hybrid-specific antibody was designed by our research group and further developed by 
Davids Biotechnologie GmbH (Regensburg, Germany). The antibody is a rabbit polyclonal 
antibody that targets the C-terminal of the CEL-HYB1 protein. More specifically, it recognizes 
a 10 amino acids sequence located in the VNTR region of the protein as illustrated in Figure 
5.11 
Figure 5.11 The epitope of the CEL-HYB specific antibody. The new antibody recognizes the 10 
amino acid sequence DRQLRVCPRP located in the VNTR region of the CEL-HYB1 protein  
 
5.7.2 Testing the CEL-HYB antibody on transfected HEK-293 and 266-6 cells 
To test the CEL-HYB antibody on cellular models, HEK-293 and the 266-6 cells were 
transfected by using Lipofectamine and nucleofection, respectively. The cells were transfected 
with plasmids encoding V5-tagged CEL-WT, CEL-HYB1, CEL-TRUNC or EV. Forty-eight h 
after transfection, the cellular fractions were prepared and analyzed by Western blotting. The 
blots were first incubated with the CEL-HYB antibody, then stripped and incubated with either 
the anti-V5 or the anti-CEL (St. Louis) antibody. The expression of GAPDH was used as a 
loading control.  
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Western blots of transfected 266-6 cells are shown in Figure 5.12A. The left panel shows 
incubation with the CEL-HYB antibody. No signal was observed for the CEL-HYB1 protein 
in any of the fractions. In the right panel, the same blot incubated with the anti-V5 antibody is 
presented. Here,  similar to Figure 5.5, all CEL variants were detected: CEL-WT, CEL-HYB1 
and CEL-TRUNC in the media, CEL-HYB1 in the pellet, and CEL-WT and CEL-HYB1 in the 
lysate fraction.  
Figure 5.12B displays the Western blots of transfected HEK-293 cells incubated with the CEL-
HYB antibody (left panel) and the anti-CEL (St. Louis) antibody (right panel). In the left panel, 
the CEL-HYB1 protein (about 64 kDa) was observed in the pellet fraction together with a high 
molecular band. The same CEL-HYB1 bands were observed in the pellet fraction in the right 
panel, when incubating with the anti-CEL antibody. In addition, CEL-TRUNC and a lower 
CEL-WT band (90 kDa) were seen in the pellet fraction. In the lysate, all three variants were 
present but only CEL-WT were detected in the media. 
Figure 5.12 Testing the CEL-HYB antibody on transfected 266-6 and HEK-293 cells. Both cell 
lines were transfected with plasmids encoding V5-tagged CEL-WT, CEL-HYB1, CEL-TRUNC or EV. 
Cellular factions were analyzed by Western blotting and incubated with the CEL-HYB antibody, 
stripped and incubated with anti-V5 antibody or anti-CEL (St. Louis) antibody. GAPDH was used as a 
loading control. The experiment was performed once. A) Analysis of cellular fraction from transfected 
266-6 cells using anti-HYB (left panel) and anti-V5 (right panel) antibodies. B) Analysis of cellular 
fractions from transfected HEK-293 cells using anti-HYB (left panel) and anti-CEL (St. Louis, right 
panel) antibodies.  
 
Based on these results, the CEL-HYB antibody works very well for the HEK-293 cells but not 
the 266-6 cells. 
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5.7.3 Testing the CEL-HYB antibody on mouse pancreatic lysates  
Next, the CEL-HYB antibody was tested on pancreatic lysates isolated from transgenic mice 
(section 4.7.6). Mice with different CEL genotypes were used: control mice (C57BL/6N (0/0)), 
heterozygous (0/ki) and homozygous (ki/ki) CEL-HYB1 knock-in mice (Section 3.1), and 
heterozygous (0/ki) 16R mice. For the latter, the mice are knocked-in with the 16 VNTR repeats 
most commonly found in the human CEL protein. The pancreatic lysates were analyzed by 
Western blotting. The membrane was first incubated with the CEL-HYB antibody, then 
stripped and incubated with the anti-CEL (St. Louis) antibody. Here, β-actin was used as 
loading control.  
As seen in Figure 5.13, only pancreatic lysates from mice containing the CEL-HYB1 knock-in 
allele tested positive when incubated with the CEL-HYB antibody. The expected band at about 
64 kDa was detected for each lysate. In contrast, when incubating with the anti-CEL antibody, 
all lysates displayed bands. The 0/0 mice lysates showed the endogenous Cel protein band at 
about 66 kDa. The heterozygous 16R mice lysates displayed two bands corresponding to the 
endogenous Cel protein (66 kDa) and the humanized 16R variant (100 -120 kDa). Similarly, 
the heterozygous CEL-HYB1 (0/ki) mice showed two bands. Here, the lower band (about 64 
kDa) is the knocked-in CEL-HYB1 protein while the upper band (about 66 kDa) is the mouse 
Cel protein. The homozygous (ki/ki) mice lysates only displayed one band at about 64 kDa. 
Figure 5.13 Testing the CEL-HYB 
antibody on mouse pancreatic lysates 
of different genotypes. Mice pancreatic 
lysates were analyzed by 
immunoblotting and incubated first with 
the hybrid-specific antibody and further 
with the anti-CEL (St. Louis) antibody. 
β-actin was used as loading control. In 
this experiment, lysates were obtained 
from control 0/0 mice, heterozygous 
(0/ki) and homozygous (ki/ki) CEL-
HYB1 knock-in mice as well as the 
heterozygous (0/ki) CEL-16R mice were 
included. The 16R mice are transgenic 
mice knocked-in with the 16 VNTR 
repeats found in the human CEL protein. 
Only the knock-in CEL-HYB1 mice 
displayed bands when incubated with 
the hybrid antibody. The experiment was 
performed once.  
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Taken together, the CEL-HYB antibody worked specifically to detect the CEL-HYB1 protein 
only in pancreatic lysates from CEL-HYB1 transgenic mice. 
 
5.8 Testing the CEL-HYB antibody on pancreatic tissue by immunohistochemistry 
During this test, we did a range of optimization steps before ending up with the optimal 
conditions for the CEL-HYB antibody. Different techniques, buffers and solutions were tested 
to determine the optimal conditions for the antibody (see Appendix 3). Briefly, we found that 
a heat-induced epitope retrieval method and the sodium-citrate buffer (pH 6.0) were best suited 
for the antibody (see Appendix 4). In addition, a high salt-containing (150 mM NaCl) antibody 
diluent enhanced the staining compared to a low salt-containing (75 mM NaCl) antibody diluent 
(see Appendix 5).  
In addition to CEL-HYB1 staining, we included staining with an anti-CEL antibody (Sigma) 
as a control. The protocol for CEL-staining was previously been optimized by our group (El 
Jellas et al., 2018). For all staining’s, we used formalin fixed and paraffin embedded mouse or 
human pancreatic tissue. 
 
5.8.1 Testing the CEL-HYB antibody on mouse pancreatic tissue 
Figure 5.14 shows CEL-HYB and CEL staining of control mice ((C57BL/6N (0/0)) and 
heterozygous (0/ki) CEL-HYB1 mice. Positive staining was shown in brown while the nuclei 
are stained blue with hematoxylin. The anti-CEL-HYB antibody showed strong and specific 
staining for the 0/ki mice in the acinar cells of the CEL-HYB1 mice whereas the control mice 
displayed a very weak background staining in the exocrine pancreas.  
As the anti-CEL antibody from Sigma recognizes amino acids within the globular domain of 
the protein, the antibody showed positive staining of the exocrine tissue in both 0/0 and 0/ki 
mice. The islets of Langerhans were negative for both antibodies, indicating that both antibodies 












Figure 5.14. CEL staining of mouse pancreatic tissue. Pancreas sections from control (C57BL/6N 
(0/0)) and heterozygous (0/ki) CEL-HYB1 mice were subjected to immunohistochemistry and analyzed 
with the anti-CEL-HYB antibody (upper panel) or the anti-CEL (Sigma) antibody (lower panel). Images 
were acquired with a Leica DM2000LED microscope with a 20x magnification. The experiment was 
performed twice.  
 
 
5.8.2 Testing the CEL-HYB antibody on human pancreatic tissue 
The CEL-HYB antibody was also tested on human pancreatic tissue, using the optimized 
protocol developed for immunohistochemistry on pancreatic mouse tissue. Human tissue from 
one patient with normal pancreas and three CEL-HYB positive pancreatic cancer patients were 
tested.  
The results are shown in Figure 5.15. Except for the control sample, all tissue showed some 
degree of positive staining for the CEL-HYB1 protein. Subject 1 showed a more intense and 
concentrated staining in the exocrine tissue than subject 2. As for the subject 3 sample, it 
exhibited an expression pattern similar to subject 1. The control tissue showed no positive 
staining for CEL-HYB1.  
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Figure 5.15. Testing the CEL-HYB antibody on human pancreatic tissue. The panel includes three  
samples of HYB1 positive origin and  one control sample. All CEL-HYB samples showed positive 
staining and the control was negative. Images were acquired with a Leica DM2000 LED microscope 








6. Discussion  
CEL-HYB1 has been identified as a genetic risk factor for chronic pancreatitis (Fjeld et al., 
2015). However, a large number of healthy individuals are carrying the CEL-HYB1 allele 
without being sick. Thus, CEL-HYB1 alone is not enough to cause chronic pancreatitis; the 
allele must act in combination with other risk factors to trigger disease development.  
 
In this study, our main objective was to gain more insight into the disease mechanism of the 
CEL-HYB1 protein. We wanted to examine if environmental factors such as alcohol and 
cigarette smoking could have any effects on the CEL-HYB1 protein in cellular and mouse 
models. In addition, a newly produced CEL-HYB1 specific antibody was tested on cellular 
fractions and tissue samples by immunoblotting and immunohistochemistry, respectively. The 
main findings and the challenges we met during this study are discussed below. 
 
6.1 The effect of CEL-HYB1 in combination with environmental factors 
 
6.1.1 The effect of alcohol and CSE on CEL-HYB1 in 266-6 cells 
We performed one parallel of CSE and EtOH treatment of transfected 266-6 cells. We used two 
concentrations of CSE (4 and 40 µg/ml) and two concentrations of EtOH (10 and 50 mM), and 
analyzed the effect by Western blotting. The concentrations were chosen based on literature. 
Concentrations of 4 and 40 µg/ml corresponding to light smoking (5 cigarettes a day) and heavy 
smoking (25 cigarettes a day), respectively. The EtOH concentrations of 10 and 50 mM 
correlate with social drinking (2 glasses a day) and heavy drinking (equivalent to ethanol 
concentration found in alcoholics) respectively (Lee and Apte, 2015, Srinivasan et al., 2015).  
First of all, when we expressed CEL-HYB1 in the 266-6 cells, we observed reduced protein 
secretion compared to CEL-WT, and CEL-HYB1 protein was detected in the insoluble pellet 
fraction (Figure 5.5).  This is similar to what we see in HEK-293 cells (Fjeld et al., 2015, Tjora 
et al., unpublished), suggesting that the protein has a tendency to aggregate also in acinar cells. 
Interestingly, when exposed to CSE, the level of CEL-HYB1 increased in the pellet fractions 
compared to cells treated with DMSO (Figure 5.7). This may suggest that the CSE have a 
negative effect on CEL-HYB1, making it more prone to protein misfolding and aggregation. 
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Also, when exposed to CSE, the CEL-HYB1N variant showed stronger bands in the pellet 
fractions than CEL-HYB1. This may suggest that the potential N-glycosylation site introduced 
to the CEL-HYB1 construct has an effect on the protein by making it more soluble. Thus, the 
CEL-HYB1N construct should selected for further analysis.  
Taken together, these results are very interesting as they indicate an interplay between CEL-
HYB1 and cigarette smoking that can trigger or accelerate chronic pancreatitis disease 
development. However, our findings need to be replicated before we draw any conclusions. An 
interesting follow up study would be to investigate the downstream effects of CEL-HYB1 and 
CSE, e.g on ER-stress. A study has shown that the effect of CSE and alcohol in combination 
induces ER-stress and cell death in both AR42J cells and primary acinar cells (Lugea et al., 
2017). Thus, they see an effect even without a genetic risk factor but only when the cells are 
exposed to both environmental factors. For additional follow up, it would be interesting to see 
if we could detect a link between CEL-HYB1 and cigarette smoking also in patients.  
We did not observe any effect of ethanol on the CEL-HYB1 protein. However, a study 
conducted by Waldron et al, detected Cel protein aggregation and increased ER-stress in 
ethanol fed mice and in AR42J cells exposed to ethanol (Waldron et al., 2018). Thus, we need 
to repeat our experiment to investigate the effect of ethanol on CEL-HYB1. We will also use 
our CEL-HYB1 mouse model as further discussed below. 
6.1.2 Ethanol feeding of heterozygous CEL-HYB1 knock-in mice  
We performed a three-week pilot experiment by exposing transgenic CEL-HYB1 knock-in mice 
to ethanol. We used the 0/0 mice as controls and the mice were pair-fed for comparison. The 
effect of the ethanol was analyzed by harvesting the pancreas for histology and Western blot 
analysis.  
During our pilot experiment, an article by Orekhova et al (Orekhova et al., 2020) was published 
on ethanol exposure using CPA1 mutant mice. Like CEL-HYB1, this CPA1 gene is implicated 
in the misfolding-dependent pathway of genetic risk in chronic pancreatitis (Mayerle et al., 
2019). The CPA1 mouse model was generated on a C57BL/6N background and they performed 
pair-feeding with the same Lieber-DeCarli diets as we did. However, their results differed from 
ours as they could clearly identify characteristics of chronic pancreatitis in their CPA1 mice. 
They concluded that ethanol feeding accelerated disease progression in the ethanol fed CPA1 
mice compared control fed CPA1 mice. A major difference between our study and Orekhova’s 
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was that they used homozygous CPA1 mice, while we used heterozygous CEL-HYB mice. In 
addition, they started the ethanol-feeding on mice at 5 weeks of age and the experiment lasted 
for 5 weeks. Orekhova et al. chose this early age as the pancreatic damage was minimal in the 
CPA1 mice at this stage and therefore the effect of ethanol could be more easily observed. In 
contrast, we used 29 weeks old mice and they were ethanol-feed for only three weeks.  
Based on these observations, we will use younger, homozygous CEL-HYB1 mice when we 
plan our next experiment. In addition, we will perform ethanol feeding for a longer period to 
investigate if this could accelerate progression of chronic pancreatitis in our CEL-HYB knock-
in mice.  
 
6.2 The specificity of the new CEL-HYB antibody 
The newly produced CEL-HYB antibody directed towards the HYB C-terminal peptide 
DRQLRVCPRP was tested for both Western blotting and immunohistochemistry. After 
optimizing the protocols thoroughly, we were excited to see that the antibody could recognize 
the CEL-HYB protein both in transfected cells, and in mouse and human pancreatic tissue.  
For the human tissues, we analyzed three CEL-HYB positive patients by 
immunohistochemistry. Subject 1 and 2 were DNA sequenced and identified as two different 
CEL-HYB forms, namely CEL-HYB1 and CEL-HYB2 (Fjeld et al., 2005, Zou et al., 2016). 
As for subject 3, DNA sequencing could not be performed as DNA was not available.  
The CEL-HYB1 sample showed strong but somewhat patchy staining in the pancreatic acinar 
cells (Figure 5.15). This could correlate with our observations of the HYB1 protein in 
transfected HEK-293 cells where it tends to accumulate within the cell (Fjeld et al., 2015). In 
contrast, the CEL-HYB2 sample displayed a more diffuse and even staining pattern. The CEL-
HYB2 gene has a premature stop codon in exon 10 leading to reduced protein expression due 
to nonsense-mediated mRNA decay (Zou et al., 2016). The observed diffuse staining pattern 
can therefore correspond to reduced protein expression. The last CEL-HYB sample, from 
subject 3, showed a strong staining pattern similar to CEL-HYB1. However, this sample needs 
to be DNA sequenced to get the exact genotype to distinguish between CEL-HYB1 and CEL-
HYB2, although the pattern was most reminiscent of the CEL-HYB1 staining pattern. 
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6.3 Study limitations and challenges 
 
6.3.1 The 266-6 cells as a model system 
Our research team have previously performed cellular experiments on the CEL-HYB1 protein 
in HEK-293 cells (Fjeld et al., 2015, Dalva et al., 2020). These cells are a reliable tool within 
experimental research, as they are easy to maintain, culture and transfect as well as having a 
high expression level of exogenously expressed proteins (Thomas et al., 2005).  Furthermore, 
the HEK-293 cells are of human origin which is important for proper post-translational 
modification of the human CEL protein (Hu et al., 2018). As a model system for pancreatic 
research, however, the main limitation of the HEK-293 cells is that they do not provide the 
proper physiological conditions as they lack the specific secretion machinery of the pancreatic 
acinar cells (Derikx et al., 2015).   
To this date there are no commercially available human acinar cell lines. Still, alternatives of 
mouse and rat origin exists. Other options are to use murine and human primary murine acinar 
cells but these are difficult to maintain for long-term cell culture experiments and they lose their 
secretory characteristics easily (Blinman et al., 2000). For this project, we chose the mouse 
acinar cell line (266-6) as a model system to study the CEL-HYB1 protein in a more proper 
environment. The 266-6 cell line endogenously expresses the mouse Cel protein and other 
digestive enzymes (Derikx et al., 2015). Our group has previously used these cells with success 
for endocytosis experiments (Torsvik et al., 2014, Dalva et al., 2020), but they have proven 
difficult to transfect as further discussed below. Furthermore, the 266-6 cells need treatment 
with dexamethasone to mature their secretory characteristics (Derikx et al., 2015). So, to study 
the expression and secretion pattern of CEL variants in 266-6 cells, the cells were stimulated 
with dexamethasone both before and after transfection of CEL constructs to ensure a proper 
acinar cell phenotype.  
In addition to the murine 266-6 cells, a rat acinar cell line (AR42J) is available that has been 
widely used in pancreatic research (examples are studies by Srinivasan et al., 2015, Xiao et al., 
2016). The AR42J-cells have also been tested by our research group. However, they lost their 
acinar specific phenotype during culturing and were therefore not used for further analysis.  
There are both pros and cons for most model system used in research and therefore one has to 
be aware of the limitations and challenges that comes with the systems. The disadvantage of 
using 266-6 cells for CEL related research is that the mouse Cel protein only contains 3 VNTR 
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repeats while the human CEL protein has 16 VNTR repeats. Therefore, translation of the human 
CEL protein in mouse acinar could be difficult due to differences in VNTR repeats. 
Furthermore, the mouse Cel protein differs from the human CEL protein with regard to post-
translation modifications like O-glycosylation (Holmes and Cox, 2011).  
6.3.2 Nucleofection and transfection efficiency  
Previously, we have transfected the 266-6 cells with Lipofectamine, but the transfection 
efficiency was quite low (~20 %). Therefore, for this project, we used nucleofection as 
transfection method. Nucleofection is a form of electroporation that allows for direct transfer 
of DNA into the nucleus. We used specific solutions and the plasmid pMAX-GFP provided by 
the manufacturers (Lonza) to optimize the nucleofection protocol for the 266-6 cells. The 
results looked very promising as we observed around 80-90 % transfection efficiency (Figure 
5.3). However, when transfecting the cells with our CEL constructs, analysis by 
immunostaining and confocal analysis revealed a transfection efficiency closer to 10-15%.  
Due to the low transfection efficiency of the CEL constructs, we contacted Lonza and they 
provided us with some troubleshooting ideas and tips (Lonza, 2012). First, they pointed out that 
the vector backbone can influence the gene expression level. They had transfected two cell lines 
(THP-1 and HUVEC cells, respectively) and tested ten different expression vectors by 
conducting a luciferase expression assay, and the pcDNA3.1 vector used in this study was 
included. They found that the pcDNA3.1 vector displayed a very poor gene expression activity 
after 48 h (our conditions) while the highest expression level was observed after 4 h. Another 
thing to consider is the vector promoter. Our pcDNA3.1-constructs includes a CMV promoter 
which is a strong promoter in many mammalian cells such as HeLa and HEK-293 cells. 
However, the CMV promoter strength has not been tested in the 266-6 cells.  
Since we do not know if the pcDNA3.1 vector backbone or promoter is appropriate for the 266-
6 cells, one way to optimize our nucleofection protocol could be to use a pcDNA3.1 construct 
that expresses GFP. Another possibility would be to clone our CEL construct into another 
vector with properties better suited for the 266-6 cells. Yet another way to improve transfection 
efficiency is to use another approach. Viral transfection has been successfully performed using 
the rat AR42J acinar cells and might be the most optimal transfection method also for the 266-
6 cells (Szmola and Sahin-Toth., 2010, Xiao et al., 2016).  
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6.3.3 The use of epitope tagged proteins 
Epitope tags fused with recombinant proteins are widely used and they are great research tools. 
Epitope tags allow for the detection of a target protein and can be used in methods such as 
immunoblotting, immunofluorescence and immunoprecipitation. Moreover, some tags are 
traceable by live-imaging allowing for in vivo localization of proteins (Lodish et al., 2013). A 
number of tags are available with different sizes and properties, and they can be coupled to the 
C-terminal or the N-terminal end of the protein depending on the protein`s function (Palmer et 
al., 2004). Unfortunately, the use of tags can also influence the experimental results and be a 
study limitation. The tags can alter the chemical properties of the protein of interest and thus 
the results obtained can either be under-or-overestimated (Booth et al., 2018).  
A study performed by our research team compared the expression of CEL protein variants with 
and without a C-terminal V5-tag in HEK-293 cells (Gravdal et al., unpublished). Here, the 
disease-causing CEL-MODY protein showed increased solubility and secretion when 
expressed with the tag compared to untagged CEL-MODY, which had a stronger tendency to 
form intracellular protein aggregates. Thus, the CEL-MODY variant showed a stronger 
pathogenic effect when expressed without the tag (Gravdal et al., unpublished). In another 
study, detection of CEL variants in the media fraction was found to be difficult when CEL was 
expressed with a C-terminal FLAG-tag (Dalva et al., 2020).   
Based on the observations above, we set out to analyze our CEL proteins variants without an 
epitope tag in this study. However, when expressed in 266-6 cells, only the CEL-WT protein 
was detected by Western blotting. CEL-HYB1 and CEL-TRUNC were not observed in any of 
the cellular fractions (Figure 5.4A). In contrast, signals for all three CEL variants were detected 
in HEK-293 cells transfected with the same untagged CEL-construct (Figure 5.4B). 
Consequently, we ended up by using V5-tagged CEL constructs also for the 266-6 cells. With 
this approach we were able to detect all CEL variants by Western blotting (Figure 5.5) and 
immunofluorescence (Figure 5.6). This is most likely due to the V5-tag making the CEL 
proteins more soluble and/or the V5-tag is easily available for the anti-V5 antibody to recognize 
the protein. 
6.3.4 Cell fractionation 
Another explanation why the CEL-HYB1 protein was not detected in the 266-6 cells could be 
due to our cell fractionation protocol. A research team in St. Louis kindly provided us with a 
protocol for cell fractionation which have proven successful for the rat acinar cell line (AR42J). 
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However, the protocol did not work well on the mouse acinar cell line as we only detected the 
CEL-WT variant. An optimal cell fractionation protocol is therefore needed to detect all CEL 
variants in 266-6 cells by immunoblotting. One more thing, the CEL-HYB1 protein is known 
to be implicated in the misfolding-dependent pathway and possibly aggregates inside the cell 
(Fjeld et al., 2015, Tjora et al., unpublished, Mayerle et al., 2019). Therefore, the antibody may 
not be able to bind to the epitope when expressed in the acinar cells.   
 
6.4 How the COVID-19 pandemic had an impact on my master project 
In spring 2020, the spread of the COVID-19 virus led to a worldwide pandemic and this virus 
had a great impact on the every-day life of most people. However, with the necessary 
restrictions put on us by the Norwegian Government, the infection was brought under control.  
For students at the University of Bergen, the restrictions involved a temporary lockdown of all 
laboratory work. The lockdown lasted for 6 weeks and consequently some of the experiments 
planned for this thesis were not performed. This mainly relates to the cellular effect of CSE and 
EtOH on CEL-HYB1. In this thesis, the results from only one experiment was presented (Figure 
5.7 and 5.8). Cellular fractions from two additional parallels were prepared but not analyzed 
due to lack of time. The plan was to conduct three parallels and to present the results with 











The main purpose of this study was to gain knowledge into the disease mechanism of the 
pathogenic CEL-HYB1 variant, a novel risk factor for chronic pancreatitis. Based on the 
findings the following conclusions can be drawn:  
 
• A protocol for successful transfection of 266-6 cells by nucleofection is established 
 
• The CEL-HYB antibody has been verified on mouse pancreatic lysates and on HEK-
293 lysates by immunoblotting 
 
• Optimization of the newly produced CEL-HYB specific antibody on mouse and human 
pancreatic tissue by immunohistochemistry has been conducted successfully 
 
 
• CSE treated CEL-HYB1N variant showed a higher propensity to accumulate in the 















8. Future perspectives  
To gain more knowledge about CEL-HYB1, and to follow up on the results from this study, we 
will focus on the experiments listed below 
 
• Further optimize the transfection efficiency/cellular fractionation protocol of the 266-6 
cells 
 
• Repeat the study on ethanol and cigarette smoking extract exposure of CEL-HYB1 
transfected 266-6 cells  
 
• Set up a new experiment for ethanol-feeding of transgenic CEL-HYB1 knock-in mice 
using younger as well as homozygous CEL-HYB1 mice, and the exposure to ethanol 
will be extended from three to five weeks 
 
• Test the CEL-HYB antibody for immunofluorescence analysis 
 
• Determine the genotype (CEL-HYB1 or CEL-HYB2) of the human sample (subject 3) 
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Appendix 1. CEL protein variants expressed with the V5-tag. All variants share identical 
signaling peptide (green) and globular domain (blue). The CEL-WT protein has 16 repeats in 
the VNTR region (grey), CEL-HYB1 variants has three repeats (red) and the CEL-TRUNC 
consists of four amino acids of the first VNTR repeat (dark blue). In contrast to CEL-HYB1, 
the CEL-HYB1N variant has a mutated N-glycosylation site within the linker region located 
between the protein and the V5/His-tag. Drawn after: Fjeld et al., 2015. Nat Genet and 







Appendix 2. Growth curves of mice fed with liquid diet. The control mice had a starting 
weight of 34-39 g while the heterozygous CEL-HYB1 mice had a starting weight of 39-40 g. 
At the end of the experiment, the control fed animals had an overall increased body weight 
ranging from 40-45 g (right panel). The trend for the ethanol fed mice was different as a 
decrease in weight was observed (left panel). Here, the final weight ranged from 34-36 g. Pair 















Appendix 3. Testing different epitope retrieval techniques for the CEL-HYB antibody. 
The heat-induced epitope retrieval (HIER), proteolytic induced epitope retrieval (PIER) and a 
detergent based epitope retrieval protocol using SDS were tested for the CEL-HYB antibody 
(5 µg/ml) on control (0/0) and CEL-HYB1 (0/ki) mouse pancreatic tissue. Brown indicated 
positive staining and the nuclei are stained blue with hematoxylin. To test the HIER method, a 
tris (pH 9), a citrate (pH 6) and a glycine buffer (pH 3.5) was used, as this covers a wide pH 
range. Here, the citrate-based buffer showed strong and specific staining compared to the tris 
and glycine buffer. Proteinase K of two concentrations (2 and 20 µg/ml) was also tested in 
addition to 1 % SDS. All images were acquired with a Leica DM2000LED microscope with 

















Appendix 4. Effect of different salt concentrations in the antibody diluent. . Epitope 
retrieval was performed using a citrate buffer (see Appendix 3) and the CEL-HYB antibody 
was diluted in either low salt (75 mM NaCl) or high salt (150 mM NaCl). Here, a big difference 
was observed for high and low salt. The staining was enhanced with a high salt containing 
antibody diluent and the background detected was higher with low salt. Therefore, a high salt-
containing diluent was selected for further use. All images are taken with a Leica DM2000LED 


















Appendix 5. Testing different citrate-based buffers for optimization of CEL-HYB 
antibody. Three buffers; citrate (commercial), citrate-EDTA and a sodium-citrate buffer were 
tested on pancreatic tissue from control (0/0) and CEL-HYB1 (0/ki) mouse. This experiment 
concluded that the sodium-citrate buffer was most optimal for the antibody as the commercial 
citrate buffer had a higher degree of background and the citrate-EDTA buffer resulted in 
staining within the islets.  All images are taken by a Leica 2000LED microscope with 20x 
magnification unless otherwise indicated in the figure.  
 
 
